The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B-DNA
enhancer	I-DNA
activation	O
following	O
stimulation	O
of	O
monocytic	B-cell_line
but	O
not	O
T-cell	B-cell_line
lines	I-cell_line
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O

While	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
binds	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	B-cell_type
versus	O
T	B-cell_type
cells	I-cell_type
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B-DNA
element	I-DNA
undergoes	O
differential	O
modification	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B-protein
B	I-protein
factor	I-protein
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
play	O
in	O
HIV	O
pathogenesis	O
.	O

JOURNAL	NULL
or	NULL
VIROLOGY	NULL
,	NULL
Aug.	NULL
1995	NULL
,	NULL
p.	NULL
4854-4862	NULL
0022-538	NULL
Copyright	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

69	NULL
,	NULL
No	NULL
.	NULL

8	NULL
The	NULL
Peri-kB	NULL
Site	NULL
Mediates	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
2	NULL
Enhancer	NULL
Activation	NULL
in	NULL
Monocytes	NULL
but	NULL
Not	NULL
in	NULL
T	NULL
Cells	NULL
NINA	NULL
M.	NULL
CLARK	NULL
,	NULL
:	NULL
MARK	NULL
C.	NULL
anp	NULL
DAVID	NULL
M.	NULL
MARKOVITZ'*	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
and	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
``	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Michigan	NULL
48109-0642	NULL
Received	NULL
23	NULL
December	NULL
1994/Accepted	NULL
8	NULL
May	NULL
1995	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
HIV-2	NULL
)	NULL
,	NULL
like	NULL
HIV-1	NULL
,	NULL
causes	NULL
AIDS	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
AIDS	NULL
cases	NULL
primarily	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL

HIV-1	NULL
and	NULL
HIV-2	NULL
display	NULL
significant	NULL
differences	NULL
in	NULL
nucleic	NULL
acid	NULL
sequence	NULL
and	NULL
in	NULL
the	NULL
natural	NULL
history	NULL
of	NULL
clinical	NULL
disease	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
differences	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
the	NULL
enhancer/promoter	NULL
region	NULL
of	NULL
HIV-2	NULL
functions	NULL
quite	NULL
differently	NULL
from	NULL
that	NULL
of	NULL
HIV-1	NULL
.	NULL

Whereas	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
following	NULL
T-cell	NULL
stimulation	NULL
is	NULL
mediated	NULL
largely	NULL
through	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-KB	NULL
to	NULL
two	NULL
adjacent	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
four	NULL
cis-acting	NULL
elements	NULL
:	NULL
a	NULL
single	NULL
xB	NULL
site	NULL
,	NULL
two	NULL
purine-rich	NULL
binding	NULL
sites	NULL
,	NULL
PuB1	NULL
and	NULL
PuB2	NULL
,	NULL
and	NULL
a	NULL
pets	NULL
site	NULL
.	NULL

We	NULL
have	NULL
now	NULL
identified	NULL
a	NULL
novel	NULL
cis-acting	NULL
element	NULL
within	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
,	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
«	NULL
B	NULL
site	NULL
,	NULL
designated	NULL
peri-	NULL
<	NULL
B	NULL
.	NULL

This	NULL
site	NULL
is	NULL
conserved	NULL
among	NULL
isolates	NULL
of	NULL
HIV-2	NULL
and	NULL
the	NULL
closely	NULL
related	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
and	NULL
transfection	NULL
assays	NULL
show	NULL
this	NULL
site	NULL
to	NULL
mediate	NULL
HIV-2	NULL
enhancer	NULL
activation	NULL
following	NULL
stimulation	NULL
of	NULL
monocytic	NULL
but	NULL
not	NULL
T-cell	NULL
lines	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
description	NULL
of	NULL
an	NULL
HIV-2	NULL
enhancer	NULL
element	NULL
which	NULL
displays	NULL
such	NULL
monocyte	NULL
specificity	NULL
,	NULL
and	NULL
no	NULL
comparable	NULL
enhancer	NULL
element	NULL
has	NULL
been	NULL
clearly	NULL
defined	NULL
for	NULL
HIV-1	NULL
.	NULL

While	NULL
a	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
from	NULL
both	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
binds	NULL
the	NULL
peri-B	NULL
site	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
suggest	NULL
that	NULL
either	NULL
a	NULL
different	NULL
protein	NULL
binds	NULL
to	NULL
this	NULL
site	NULL
in	NULL
monocytes	NULL
versus	NULL
T	NULL
cells	NULL
or	NULL
that	NULL
the	NULL
protein	NULL
recognizing	NULL
this	NULL
enhancer	NULL
element	NULL
undergoes	NULL
differential	NULL
modification	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
thus	NULL
supporting	NULL
the	NULL
transfection	NULL
data	NULL
.	NULL

Further	NULL
,	NULL
while	NULL
specific	NULL
constitutive	NULL
binding	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
seen	NULL
in	NULL
monocytes	NULL
,	NULL
stimulation	NULL
with	NULL
phorbol	NULL
esters	NULL
induces	NULL
additional	NULL
,	NULL
specific	NULL
binding	NULL
.	NULL

Understanding	NULL
the	NULL
monocyte-specific	NULL
function	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
may	NULL
ultimately	NULL
provide	NULL
insight	NULL
into	NULL
the	NULL
different	NULL
roles	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
play	NULL
in	NULL
HIV	NULL
pathogenesis	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
HIV-2	NULL
)	NULL
,	NULL
like	NULL
HIV-1	NULL
,	NULL
causes	NULL
AIDS	NULL
(	NULL
1	NULL
,	NULL
9	NULL
,	NULL
11	NULL
,	NULL
63	NULL
)	NULL
.	NULL

While	NULL
HIV-2	NULL
infection	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
AIDS	NULL
cases	NULL
in	NULL
West	NULL
Africa	NULL
(	NULL
1	NULL
,	NULL
9-11	NULL
,	NULL
13	NULL
,	NULL
63	NULL
)	NULL
,	NULL
it	NULL
is	NULL
also	NULL
becoming	NULL
increasingly	NULL
recognized	NULL
in	NULL
other	NULL
areas	NULL
of	NULL
the	NULL
world	NULL
(	NULL
1	NULL
,	NULL
11-13	NULL
,	NULL
48	NULL
,	NULL
63	NULL
)	NULL
.	NULL

The	NULL
genomes	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
encode	NULL
similar	NULL
viral	NULL
proteins	NULL
,	NULL
but	NULL
HIV-2	NULL
shares	NULL
only	NULL
approximately	NULL
42	NULL
%	NULL
nucleic	NULL
acid	NULL
sequence	NULL
similarity	NULL
with	NULL
HIV-1	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
and	NULL
is	NULL
instead	NULL
more	NULL
closely	NULL
related	NULL
to	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
,	NULL
with	NULL
which	NULL
HIV-2	NULL
shares	NULL
75	NULL
%	NULL
or	NULL
more	NULL
sequence	NULL
similarity	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
strain	NULL
(	NULL
6	NULL
,	NULL
23	NULL
)	NULL
.	NULL

HIV-1	NULL
and	NULL
HIV-2	NULL
not	NULL
only	NULL
display	NULL
significant	NULL
nucleic	NULL
acid	NULL
sequence	NULL
differences	NULL
but	NULL
also	NULL
show	NULL
striking	NULL
biological	NULL
and	NULL
clinical	NULL
differences	NULL
.	NULL

HIV-2	NULL
infection	NULL
progresses	NULL
to	NULL
AIDS	NULL
much	NULL
more	NULL
slowly	NULL
than	NULL
HIV-1	NULL
infection	NULL
does	NULL
and	NULL
demonstrates	NULL
less	NULL
efficient	NULL
perinatal	NULL
and	NULL
heterosexual	NULL
transmission	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
13	NULL
,	NULL
37-39	NULL
,	NULL
48	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
tissue	NULL
culture	NULL
experiments	NULL
,	NULL
mono-clonal	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
component	NULL
CD3	NULL
stimulate	NULL
production	NULL
of	NULL
HIV-2	NULL
but	NULL
not	NULL
HIV-1	NULL
from	NULL
latently	NULL
infected	NULL
T-cell	NULL
lines	NULL
,	NULL
and	NULL
HIV-2	NULL
is	NULL
less	NULL
responsive	NULL
to	NULL
stimulation	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
than	NULL
HIV-1	NULL
(	NULL
33	NULL
,	NULL
49	NULL
)	NULL
.	NULL

The	NULL
clinical	NULL
differences	NULL
between	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
infection	NULL
remain	NULL
largely	NULL
unexplained	NULL
,	NULL
and	NULL
it	NULL
is	NULL
unknown	NULL
,	NULL
for	NULL
example	NULL
,	NULL
why	NULL
HIV-2	NULL
infection	NULL
displays	NULL
a	NULL
much	NULL
more	NULL
prolonged	NULL
period	NULL
of	NULL
clinical	NULL
latency	NULL
than	NULL
HIV-1	NULL
infection	NULL
does	NULL
.	NULL

A	NULL
correlation	NULL
between	NULL
clinical	NULL
latency	NULL
and	NULL
latency	NULL
of	NULL
HIV	NULL
on	NULL
a	NULL
cellular	NULL
level	NULL
has	NULL
been	NULL
suspected	NULL
.	NULL

Following	NULL
infection	NULL
of	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
HIV	NULL
expression	NULL
is	NULL
suppressed	NULL
for	NULL
a	NULL
variable	NULL
period	NULL
of	NULL
time	NULL
until	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
6301	NULL
MSRB	NULL
III	NULL
,	NULL
1150	NULL
W.	NULL
Medical	NULL
Center	NULL
Dr.	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
48109-0642	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
313	NULL
)	NULL
747-1786	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
313	NULL
)	NULL
936-9220	NULL
.	NULL

4854	NULL
cellular	NULL
conditions	NULL
are	NULL
altered	NULL
such	NULL
that	NULL
they	NULL
permit	NULL
replication	NULL
of	NULL
the	NULL
virus	NULL
(	NULL
20	NULL
,	NULL
44	NULL
,	NULL
49	NULL
,	NULL
56	NULL
)	NULL
.	NULL

In	NULL
asymptomatic	NULL
HIV-infected	NULL
individuals	NULL
,	NULL
the	NULL
number	NULL
of	NULL
infected	NULL
cells	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
is	NULL
low	NULL
and	NULL
it	NULL
is	NULL
often	NULL
difficult	NULL
to	NULL
demonstrate	NULL
viral	NULL
expression	NULL
in	NULL
these	NULL
infected	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Disease	NULL
progression	NULL
is	NULL
associated	NULL
with	NULL
marked	NULL
increases	NULL
in	NULL
viral	NULL
expression	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Recently	NULL
it	NULL
has	NULL
been	NULL
noted	NULL
that	NULL
there	NULL
may	NULL
be	NULL
a	NULL
preferential	NULL
localization	NULL
of	NULL
HIV-infected	NULL
cells	NULL
actively	NULL
producing	NULL
virus	NULL
in	NULL
the	NULL
lymphoid	NULL
tissue	NULL
early	NULL
in	NULL
HIV-1	NULL
infection	NULL
,	NULL
despite	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
16	NULL
,	NULL
59	NULL
)	NULL
.	NULL

However	NULL
,	NULL
even	NULL
in	NULL
the	NULL
lymph	NULL
nodes	NULL
,	NULL
cellular	NULL
latency	NULL
is	NULL
an	NULL
important	NULL
phenomenon	NULL
,	NULL
as	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
only	NULL
a	NULL
small	NULL
percentage	NULL
of	NULL
infected	NULL
lymphoid	NULL
cells	NULL
are	NULL
actively	NULL
making	NULL
virus	NULL
at	NULL
any	NULL
given	NULL
time	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
cytokines	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
or	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
increases	NULL
transcription	NULL
of	NULL
HIV	NULL
via	NULL
cellular	NULL
intermediaries	NULL
(	NULL
21	NULL
,	NULL
33	NULL
,	NULL
41	NULL
,	NULL
49	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
exposure	NULL
of	NULL
HIV-infected	NULL
macrophages	NULL
and	NULL
monocytes	NULL
to	NULL
activated	NULL
,	NULL
uninfected	NULL
T	NULL
cells	NULL
or	NULL
to	NULL
cytokines	NULL
can	NULL
induce	NULL
HIV	NULL
replication	NULL
(	NULL
21	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
61	NULL
,	NULL
65	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
recent	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
level	NULL
of	NULL
HIV	NULL
mRNA	NULL
expression	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
in	NULL
asymptomatic	NULL
HIV-infected	NULL
persons	NULL
correlates	NULL
with	NULL
clinical	NULL
disease	NULL
progression	NULL
over	NULL
the	NULL
subsequent	NULL
2	NULL
to	NULL
5	NULL
years	NULL
(	NULL
64	NULL
)	NULL
.	NULL

Since	NULL
progression	NULL
of	NULL
clinical	NULL
disease	NULL
is	NULL
associated	NULL
with	NULL
and	NULL
likely	NULL
accelerated	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
viral	NULL
replication	NULL
,	NULL
we	NULL
have	NULL
been	NULL
interested	NULL
in	NULL
the	NULL
cellular	NULL
events	NULL
involved	NULL
in	NULL
effecting	NULL
the	NULL
transition	NULL
from	NULL
HIV	NULL
latency	NULL
to	NULL
replication	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
differences	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
observed	NULL
differences	NULL
in	NULL
the	NULL
clinical	NULL
latency	NULL
period	NULL
following	NULL
infection	NULL
with	NULL
these	NULL
viruses	NULL
.	NULL

In	NULL
studying	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
HIV-2	NULL
,	NULL
we	NULL
and	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
-200	NULL
PuB2	NULL
-143	NULL
-130	NULL
HIV-2	NULL
ENHANCER	NULL
ACTIVATION	NULL
IN	NULL
MONOCYTES	NULL
BY	NULL
PERI-	NULL
«	NULL
B	NULL
4855	NULL
Sp1	NULL
TATA	NULL
-	NULL
cap	NULL
translation	NULL
box	NULL
site	NULL
initiation	NULL
ntt	NULL
-/	NULL
coum	NULL
|	NULL
-30	NULL
+1	NULL
+156	NULL
189	NULL
PuB1	NULL
(	NULL
CD3R	NULL
)	NULL
-160	NULL
pets	NULL
TGAAAGCAAGAGGAATACCATTTAGTITIAAAGACAGGAACAGCTATAC	NULL
[	NULL
ITGGTCAGCGG	NULL
peri-KB	NULL
110	NULL
KB	NULL
=84	NULL
1	NULL
ACTAACAIGAAACAGCTGAGACTGC|AGGGACT1TCCVAGAAGGGGCTGTAACC	NULL
Mutant	NULL
:	NULL
__	NULL
GgaATTC	NULL
(	NULL
A	NULL
)	NULL
:	NULL
CTCGAGTACT	NULL
ATCT	NULL
(	NULL
B	NULL
)	NULL
:	NULL
TAAGCTT	NULL
B	NULL
__	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Enhancer	NULL
{	NULL
egion	NULL
of	NULL
HIV-2	NULL
.	NULL

RelcYant	NULL
sites	NULL
within	NULL
the	NULL
LTR	NULL
are	NULL
CONSENSUS	NULL
aaac	NULL
?	NULL

abctgagac	NULL
?	NULL

6C	NULL
Sﬁgtlﬁed	NULL
.	NULL

Altered	NULL
bases	NULL
within	NULL
the	NULL
mutant	NULL
p1asm1§s	NULL
u5§d	NULL
are	NULL
s.hown	NULL
below	NULL
the	NULL
-type	NULL
sequence	NULL
;	NULL
(	NULL
A	NULL
)	NULL
denotes	NULL
the	NULL
mutation	NULL
contained	NULL
in	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
,	NULL
and	NULL
(	NULL
B	NULL
)	NULL
HIV-2	NULL
ROD	NULL
GAAACAGCTGAGACTGC	NULL
denotes	NULL
the	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
B	NULL
)	NULL
mutation	NULL
.	NULL

The	NULL
Aperi-	NULL
<	NULL
B	NULL
(	NULL
A	NULL
)	NULL
+A	NULL
«	NULL
B	NULL
mutant	NULL
plasmid	NULL
con-HIV-2	NULL
NIHZ	NULL
.	NULL

GAACAGCTGAGACTGC	NULL
tains	NULL
both	NULL
the	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
and	NULL
the	NULL
AB	NULL
mutations	NULL
.	NULL

The	NULL
PuB1	NULL
,	NULL
PuB2	NULL
,	NULL
pets	NULL
,	NULL
and	NULL
HIV-2	NULL
ISY	NULL
.	NULL

AAACAGCTGAGACTGC	NULL
kB	NULL
sites	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
49	NULL
,	NULL
51	NULL
)	NULL
,	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
HIV-2.,4	NULL
_	NULL
has	NULL
been	NULL
published	NULL
elsewhere	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Site-directed	NULL
mutations	NULL
were	NULL
introduced	NULL
by	NULL
HIV-2	NULL
ST	NULL
«	NULL
AAACAGCTGAGACT	NULL
GC	NULL
the	NULL
gap-heteroduplex	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
56	NULL
)	NULL
.	NULL

CAT	NULL
,	NULL
chloramphen-HIV-2	NULL
BEN	NULL
«	NULL
AAACAGCTGAGGCTGC	NULL
icol	NULL
acetyltransferase	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Conserved	NULL
nucleotides	NULL
in	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
region	NULL
of	NULL
the	NULL
HIV-2	NULL
CAMZ	NULL
.	NULL

AAACAGCTGAGACTGC	NULL
LTRs	NULL
of	NULL
HIV-2	NULL
and	NULL
SIV	NULL
isolates	NULL
,	NULL
modified	NULL
from	NULL
Myers	NULL
et	NULL
al	NULL
.	NULL

(	NULL
55	NULL
)	NULL
.	NULL

Uppercase	NULL
HIV-2	NULL
D194	NULL
.	NULL

AA	NULL
.	NULL

CAGCTGAGACTGC	NULL
letters	NULL
in	NULL
the	NULL
consensus	NULL
sequence	NULL
indicate	NULL
100	NULL
%	NULL
conservation	NULL
of	NULL
nucleotide	NULL
bases	NULL
HIV-2	NULL
GH1	NULL
GCTGAGGCTocAcCcToc	NULL
in	NULL
a	NULL
given	NULL
.	NULL

position	NULL
of	NULL
the	NULL
alignment	NULL
,	NULL
and	NULL
lowgcasc	NULL
letters	NULL
represent	NULL
bases	NULL
HIV-2	NULL
D205	NULL
AAACTAGCAGACACTGC	NULL
gifiﬁiiefssgetiszggzﬁ	NULL
:	NULL
$	NULL
;	NULL
ZE	NULL
:	NULL
SI	NULL
?	NULL

CSS	NULL
examined	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Dots	NULL
are	NULL
introduced	NULL
SIV	NULL
MM251	NULL
AAACTCGCTGAGATAGC	NULL
SIV	NULL
AAACTAGATGAGACAGC	NULL
SIV	NULL
MM32H	NULL
AAACTCGCTGAGACAGC	NULL
SIV	NULL
MM142	NULL
AAACTAGCTGACACAGC	NULL
binding	NULL
sites	NULL
,	NULL
designated	NULL
PuB1	NULL
and	NULL
PuB2	NULL
,	NULL
and	NULL
a	NULL
pets	NULL
(	NULL
peri-ets	NULL
)	NULL
SIV	NULL
MM239	NULL
AAACTCGCTGAAACAGC	NULL
site	NULL
,	NULL
located	NULL
between	NULL
the	NULL
PuB	NULL
sites	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
43	NULL
,	NULL
49	NULL
,	NULL
51	NULL
)	NULL
.	NULL

SIV	NULL
MNE	NULL
AAACTAGCTGAGACAGC	NULL
The	NULL
purine-rich	NULL
PuBl	NULL
and	NULL
PuB2	NULL
sites	NULL
contain	NULL
the	NULL
conserved	NULL
SIV	NULL
SMMHA4	NULL
AAACAAGCTGAGACAGC	NULL
GGA	NULL
core	NULL
binding	NULL
motif	NULL
which	NULL
is	NULL
recognized	NULL
by	NULL
members	NULL
of	NULL
SIV	NULL
SMMPBJ	NULL
AAACAAGCTAAGACAGC	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
proto-oncogenes	NULL
(	NULL
43	NULL
,	NULL
67	NULL
,	NULL
69	NULL
)	NULL
.	NULL

The	NULL
predomi-SIV	NULL
STAK1	NULL
AAACAAGCTGAGACGGC	NULL
nant	NULL
protein	NULL
binding	NULL
the	NULL
PuB	NULL
sites	NULL
in	NULL
vivo	NULL
appears	NULL
to	NULL
be	NULL
Elf-1	NULL
,	NULL
SIV	NULL
STM	NULL
AAACAAGCTGAGACAGC	NULL
others	NULL
have	NULL
found	NULL
that	NULL
the	NULL
enhancer/promoter	NULL
region	NULL
of	NULL
HIV-2	NULL
,	NULL
located	NULL
in	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
,	NULL
functions	NULL
quite	NULL
differently	NULL
from	NULL
that	NULL
of	NULL
HIV-1	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
(	NULL
33	NULL
,	NULL
35	NULL
,	NULL
43	NULL
,	NULL
49	NULL
,	NULL
51	NULL
,	NULL
68	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhance-er/promoter	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
mediated	NULL
predominantly	NULL
by	NULL
binding	NULL
of	NULL
the	NULL
cellular	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
two	NULL
adjacent	NULL
kB	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
50	NULL
,	NULL
56	NULL
)	NULL
.	NULL

The	NULL
HIV-2	NULL
enhancer	NULL
,	NULL
unlike	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
,	NULL
contains	NULL
only	NULL
a	NULL
single	NULL
functional	NULL
kB	NULL
element	NULL
and	NULL
also	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
other	NULL
inducible	NULL
cis-acting	NULL
elements	NULL
which	NULL
we	NULL
have	NULL
previously	NULL
described	NULL
:	NULL
two	NULL
purine-rich	NULL
an	NULL
Ets	NULL
family	NULL
member	NULL
which	NULL
is	NULL
related	NULL
to	NULL
the	NULL
Drosophila	NULL
development	NULL
protein	NULL
E74	NULL
(	NULL
35	NULL
,	NULL
43	NULL
)	NULL
.	NULL

The	NULL
PuB	NULL
and	NULL
pets	NULL
sites	NULL
of	NULL
HIV-2	NULL
are	NULL
not	NULL
found	NULL
in	NULL
HIV-1	NULL
but	NULL
are	NULL
conserved	NULL
among	NULL
HIV-2	NULL
isolates	NULL
and	NULL
are	NULL
also	NULL
found	NULL
in	NULL
another	NULL
human	NULL
pathogenic	NULL
ret-rovirus	NULL
,	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
8	NULL
)	NULL
.	NULL

These	NULL
sites	NULL
are	NULL
important	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
phorbol	NULL
esters	NULL
,	NULL
phytohemagglutinin	NULL
,	NULL
antibody	NULL
to	NULL
the	NULL
CD3	NULL
component	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
complex	NULL
,	NULL
and	NULL
antigen	NULL
(	NULL
33	NULL
,	NULL
34	NULL
,	NULL
49	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
transcriptional	NULL
regulation	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
have	NULL
also	NULL
been	NULL
noted	NULL
in	NULL
monocytic	NULL
cells	NULL
,	NULL
which	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
HIV	NULL
infection	NULL
.	NULL

It	NULL
is	NULL
believed	NULL
that	NULL
monocytes	NULL
act	NULL
as	NULL
a	NULL
reservoir	NULL
for	NULL
HIV	NULL
in	NULL
vivo	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-related	NULL
encephalopathy	NULL
(	NULL
24	NULL
,	NULL
25	NULL
,	NULL
35	NULL
,	NULL
58	NULL
,	NULL
4856	NULL
CLARK	NULL
ET	NULL
AL	NULL
.	NULL

71	NULL
)	NULL
.	NULL

Griffin	NULL
et	NULL
al	NULL
.	NULL

have	NULL
shown	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
in	NULL
immature	NULL
monocytic	NULL
cell	NULL
lines	NULL
by	NULL
phorbol	NULL
myr-istate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NF-kB	NULL
and	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
mature	NULL
monocytes	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
constitutively	NULL
expressed	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
high	NULL
level	NULL
of	NULL
basal	NULL
expression	NULL
of	NULL
HIV-1	NULL
and	NULL
lack	NULL
of	NULL
induction	NULL
by	NULL
PMA	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
HIV-2	NULL
expression	NULL
in	NULL
monocytes	NULL
following	NULL
PMA	NULL
stimulation	NULL
requires	NULL
intact	NULL
PuB	NULL
and	NULL
pets	NULL
enhancer	NULL
sites	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
kB	NULL
site	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
different	NULL
clinical	NULL
and	NULL
biological	NULL
characteristics	NULL
of	NULL
infection	NULL
with	NULL
HIV-1	NULL
compared	NULL
with	NULL
HIV-2	NULL
may	NULL
thus	NULL
in	NULL
part	NULL
be	NULL
a	NULL
result	NULL
of	NULL
the	NULL
different	NULL
patterns	NULL
of	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
two	NULL
viruses	NULL
.	NULL

In	NULL
the	NULL
course	NULL
of	NULL
performing	NULL
DNase	NULL
protection	NULL
analysis	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
,	NULL
a	NULL
footprint	NULL
was	NULL
noted	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
xB	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
this	NULL
DNA	NULL
sequence	NULL
revealed	NULL
that	NULL
the	NULL
motif	NULL
,	NULL
designated	NULL
the	NULL
peri-kB	NULL
site	NULL
,	NULL
is	NULL
conserved	NULL
across	NULL
isolates	NULL
of	NULL
HIV-2	NULL
and	NULL
SIV	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
(	NULL
55	NULL
)	NULL
and	NULL
appears	NULL
to	NULL
be	NULL
unique	NULL
.	NULL

Given	NULL
these	NULL
findings	NULL
and	NULL
the	NULL
proximity	NULL
of	NULL
the	NULL
site	NULL
to	NULL
kB	NULL
,	NULL
we	NULL
were	NULL
interested	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
to	NULL
confer	NULL
,	NULL
along	NULL
with	NULL
the	NULL
other	NULL
cis-acting	NULL
elements	NULL
,	NULL
inducible	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
and/or	NULL
monocytes	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
described	NULL
below	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
peri-xB	NULL
site	NULL
is	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
HIV-2	NULL
enhancer	NULL
function	NULL
in	NULL
monocytes	NULL
but	NULL
unlike	NULL
the	NULL
PuB1	NULL
,	NULL
PuB2	NULL
,	NULL
pets	NULL
,	NULL
and	NULL
kB	NULL
sites	NULL
,	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
site	NULL
leads	NULL
to	NULL
markedly	NULL
diminished	NULL
transcriptional	NULL
activation	NULL
following	NULL
stimulation	NULL
in	NULL
monocytic	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
is	NULL
specifically	NULL
recognized	NULL
by	NULL
either	NULL
a	NULL
different	NULL
cellular	NULL
protein	NULL
in	NULL
monocytes	NULL
than	NULL
in	NULL
T	NULL
cells	NULL
or	NULL
by	NULL
a	NULL
single	NULL
protein	NULL
which	NULL
is	NULL
differentially	NULL
modified	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
types	NULL
.	NULL

A	NULL
monocyte-specific	NULL
transcriptional	NULL
activator	NULL
has	NULL
not	NULL
previously	NULL
been	NULL
described	NULL
for	NULL
HIV-2	NULL
or	NULL
clearly	NULL
delineated	NULL
for	NULL
HIV-1	NULL
,	NULL
and	NULL
such	NULL
a	NULL
finding	NULL
suggests	NULL
one	NULL
possible	NULL
cellular	NULL
regulatory	NULL
mechanism	NULL
which	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
different	NULL
roles	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
play	NULL
in	NULL
HIV	NULL
pathogenesis	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmids	NULL
.	NULL

Construction	NULL
of	NULL
HIV-2/CAT	NULL
and	NULL
HIV-2	NULL
A	NULL
«	NULL
B/CAT	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
17	NULL
,	NULL
49	NULL
)	NULL
.	NULL

HIV-2	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
/CAT	NULL
,	NULL
HIV-2	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
B	NULL
)	NULL
/CAT	NULL
,	NULL
HIV-2	NULL
peri-	NULL
«	NULL
B	NULL
DEL	NULL
(	NULL
-111	NULL
,	NULL
-127/CAT	NULL
,	NULL
and	NULL
HIV-2	NULL
Aperi-	NULL
«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
+A	NULL
«	NULL
B/CAT	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
were	NULL
constructed	NULL
by	NULL
using	NULL
the	NULL
gap-heteroduplex	NULL
site-specific	NULL
mutagenesis	NULL
protocol	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
56	NULL
)	NULL
.	NULL

The	NULL
HIV-2	NULL
mutants	NULL
were	NULL
sequenced	NULL
by	NULL
the	NULL
dideoxy	NULL
method	NULL
(	NULL
kit	NULL
from	NULL
U.S.	NULL
Biochemical	NULL
)	NULL
.	NULL

Cell	NULL
transfections	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
assays	NULL
.	NULL

The	NULL
Jurkat	NULL
T	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
CEM	NULL
T	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
the	NULL
U937	NULL
monocytic	NULL
cell	NULL
line	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
prior	NULL
to	NULL
transfection	NULL
and	NULL
RPMI	NULL
with	NULL
5	NULL
%	NULL
FBS	NULL
after	NULL
transfection	NULL
.	NULL

The	NULL
HL-60	NULL
cell	NULL
line	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
with	NULL
20	NULL
%	NULL
FBS	NULL
before	NULL
and	NULL
after	NULL
transfection	NULL
.	NULL

The	NULL
THP-1	NULL
monocytic	NULL
cell	NULL
line	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
50	NULL
M	NULL
B-mercaptocthanol	NULL
before	NULL
and	NULL
after	NULL
transfection	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
under	NULL
standard	NULL
conditions	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
plasmid	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Twenty	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
certain	NULL
cell	NULL
groups	NULL
were	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
20	NULL
h	NULL
with	NULL
16	NULL
nM	NULL
PMA	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
normalized	NULL
by	NULL
protein	NULL
concentration	NULL
.	NULL

DNase	NULL
protection	NULL
assays	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
Jurkat	NULL
extract	NULL
was	NULL
additionally	NULL
purified	NULL
through	NULL
a	NULL
KCI	NULL
step	NULL
gradient	NULL
,	NULL
with	NULL
the	NULL
fraction	NULL
eluting	NULL
at	NULL
0.4	NULL
M	NULL
being	NULL
used	NULL
.	NULL

For	NULL
the	NULL
assays	NULL
using	NULL
HeLa	NULL
cell	NULL
extracts	NULL
,	NULL
a	NULL
radiolabeled	NULL
antisense	NULL
strand	NULL
probe	NULL
extending	NULL
from	NULL
-51	NULL
to	NULL
-231	NULL
was	NULL
used	NULL
.	NULL

For	NULL
the	NULL
experiments	NULL
using	NULL
U937	NULL
nuclear	NULL
extracts	NULL
,	NULL
both	NULL
radiolabeled	NULL
sense	NULL
and	NULL
antisense	NULL
strand	NULL
probes	NULL
extending	NULL
from	NULL
-96	NULL
to	NULL
-147	NULL
were	NULL
employed	NULL
,	NULL
and	NULL
the	NULL
probes	NULL
contained	NULL
mutations	NULL
in	NULL
both	NULL
the	NULL
PuB2	NULL
and	NULL
«	NULL
B	NULL
sites	NULL
(	NULL
the	NULL
sequences	NULL
of	NULL
these	NULL
mutations	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

For	NULL
the	NULL
experiments	NULL
using	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
,	NULL
a	NULL
radiolabeled	NULL
sense	NULL
strand	NULL
probe	NULL
extending	NULL
from	NULL
-110	NULL
to	NULL
-190	NULL
was	NULL
employed	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
generated	NULL
and	NULL
DNase	NULL
protection	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
15	NULL
,	NULL
22	NULL
,	NULL
49	NULL
,	NULL
51	NULL
)	NULL
.	NULL

EMSAs	NULL
.	NULL

Jurkat	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
HL-60	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
from	NULL
cells	NULL
which	NULL
were	NULL
either	NULL
unstimulated	NULL
or	NULL
treated	NULL
for	NULL
5	NULL
to	NULL
8	NULL
h	NULL
with	NULL
16	NULL
nM	NULL
PMA	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
as	NULL
follows	NULL
:	NULL
buffy	NULL
coats	NULL
prepared	NULL
by	NULL
the	NULL
American	NULL
Red	NULL
Cross	NULL
from	NULL
samples	NULL
of	NULL
whole	NULL
blood	NULL
from	NULL
healthy	NULL
donors	NULL
were	NULL
diluted	NULL
1:2	NULL
with	NULL
phosphate-buiffered	NULL
saline	NULL
and	NULL
J.	NULL
ViroL	NULL
.	NULL

layered	NULL
onto	NULL
Histopaque-1077	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
at	NULL
25°C	NULL
,	NULL
and	NULL
the	NULL
mononuclear	NULL
cell	NULL
layer	NULL
was	NULL
aspirated	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
RPMI	NULL
containing	NULL
5	NULL
%	NULL
FBS	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
layered	NULL
on	NULL
a	NULL
continuous	NULL
Percoll	NULL
(	NULL
Pharmacia	NULL
)	NULL
gradient	NULL
and	NULL
centrifuged	NULL
at	NULL
1,000	NULL
x	NULL
g	NULL
for	NULL
20	NULL
min	NULL
for	NULL
separation	NULL
of	NULL
monocytic	NULL
cells	NULL
from	NULL
lymphocytes	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
were	NULL
aspirated	NULL
separately	NULL
,	NULL
and	NULL
each	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
RPMI	NULL
containing	NULL
5	NULL
%	NULL
FBS	NULL
.	NULL

Unstimulated	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
half	NULL
of	NULL
the	NULL
monocytes	NULL
(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
the	NULL
rest	NULL
were	NULL
incubated	NULL
with	NULL
16	NULL
nM	NULL
PMA	NULL
in	NULL
RPMI	NULL
with	NULL
5	NULL
%	NULL
FBS	NULL
at	NULL
37°C	NULL
for	NULL
6	NULL
to	NULL
8	NULL
h.	NULL
Nuclear	NULL
extracts	NULL
were	NULL
subsequently	NULL
prepared	NULL
from	NULL
these	NULL
cells	NULL
as	NULL
well	NULL
.	NULL

The	NULL
lymphocytes	NULL
were	NULL
layered	NULL
onto	NULL
a	NULL
discontinuous	NULL
Percoll	NULL
gradient	NULL
and	NULL
centrifuged	NULL
at	NULL
1,750	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
to	NULL
separate	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
T	NULL
cells	NULL
were	NULL
aspirated	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
RPMI	NULL
containing	NULL
5	NULL
%	NULL
FBS	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
sense	NULL
and	NULL
antisense	NULL
strands	NULL
for	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
used	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
were	NULL
synthesized	NULL
with	NULL
an	NULL
Applied	NULL
Biosystems	NULL
300B	NULL
synthesizer	NULL
.	NULL

The	NULL
sequence	NULL
corresponded	NULL
to	NULL
positions	NULL
-111	NULL
to	NULL
-137	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
single-stranded	NULL
oligonucleotides	NULL
were	NULL
purified	NULL
on	NULL
a	NULL
15	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
each	NULL
strand	NULL
was	NULL
labeled	NULL
with	NULL
polynucleotide	NULL
kinase	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-PJATP	NULL
.	NULL

Equimolar	NULL
amounts	NULL
of	NULL
each	NULL
strand	NULL
were	NULL
annealed	NULL
by	NULL
incubation	NULL
at	NULL
80°C	NULL
followed	NULL
by	NULL
slow	NULL
cooling	NULL
in	NULL
500	NULL
mM	NULL
NaCl	NULL
The	NULL
double-stranded	NULL
probe	NULL
was	NULL
then	NULL
purified	NULL
with	NULL
a	NULL
Sephadex	NULL
G-50	NULL
column	NULL
.	NULL

The	NULL
peri-	NULL
«	NULL
B	NULL
(	NULL
C	NULL
)	NULL
oligonucleotide	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
consisted	NULL
of	NULL
the	NULL
sequence	NULL
corresponding	NULL
to	NULL
positions	NULL
-111	NULL
to	NULL
-135	NULL
,	NULL
the	NULL
xB	NULL
competitor	NULL
oligonucleotide	NULL
consisted	NULL
of	NULL
the	NULL
sequence	NULL
corresponding	NULL
to	NULL
positions	NULL
-93	NULL
to	NULL
-114	NULL
,	NULL
the	NULL
AB	NULL
competitor	NULL
oligonucleotide	NULL
corresponded	NULL
to	NULL
positions	NULL
-93	NULL
to	NULL
-114	NULL
with	NULL
positions	NULL
-105	NULL
to	NULL
-108	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
the	NULL
PuB1	NULL
competitor	NULL
sequence	NULL
corresponded	NULL
to	NULL
positions	NULL
-151	NULL
to	NULL
-182	NULL
,	NULL
and	NULL
the	NULL
pets	NULL
competitor	NULL
sequence	NULL
corresponded	NULL
to	NULL
positions	NULL
-131	NULL
to	NULL
-162	NULL
with	NULL
the	NULL
PuB2	NULL
site	NULL
mutated	NULL
at	NULL
positions	NULL
-137	NULL
to	NULL
-142	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

These	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
an	NULL
Applied	NULL
Biosystems	NULL
300B	NULL
synthesizer	NULL
and	NULL
were	NULL
annealed	NULL
in	NULL
an	NULL
identical	NULL
manner	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
probe	NULL
described	NULL
above	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
for	NULL
the	NULL
EMSAs	NULL
(	NULL
8	NULL
,	NULL
30	NULL
,	NULL
49	NULL
,	NULL
66	NULL
)	NULL
contained	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
,	NULL
500	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
and	NULL
15,000	NULL
epm	NULL
of	NULL
radiolabeled	NULL
oligonucleotide	NULL
probe	NULL
in	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
0.1	NULL
M	NULL
NaCl	NULL
,	NULL
and	NULL
4	NULL
%	NULL
glycerol	NULL
in	NULL
a	NULL
final	NULL
reaction	NULL
volume	NULL
of	NULL
20	NULL
wl	NULL
.	NULL

Following	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
15	NULL
min	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
run	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
TGE	NULL
buffer	NULL
(	NULL
0.05	NULL
M	NULL
Tris	NULL
,	NULL
0.5	NULL
M	NULL
glycine	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
100	NULL
V	NULL
for	NULL
2.5	NULL
h.	NULL
RESULTS	NULL
The	NULL
peri-B	NULL
site	NULL
is	NULL
recognized	NULL
by	NULL
a	NULL
nuclear	NULL
factor	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
the	NULL
sequence	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
xB	NULL
site	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
,	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
is	NULL
conserved	NULL
among	NULL
isolates	NULL
of	NULL
HIV-2	NULL
and	NULL
SIV	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

DNase	NULL
footprint	NULL
analysis	NULL
was	NULL
performed	NULL
,	NULL
initially	NULL
with	NULL
unstimulated	NULL
HeLa	NULL
cells	NULL
,	NULL
and	NULL
revealed	NULL
two	NULL
footprints	NULL
:	NULL
one	NULL
which	NULL
included	NULL
the	NULL
xB	NULL
site	NULL
as	NULL
well	NULL
as	NULL
5	NULL
bp	NULL
upstream	NULL
and	NULL
4	NULL
bp	NULL
down-stream	NULL
;	NULL
and	NULL
a	NULL
second	NULL
footprint	NULL
farther	NULL
upstream	NULL
of	NULL
the	NULL
xB	NULL
site	NULL
,	NULL
located	NULL
between	NULL
positions	NULL
-123	NULL
and	NULL
-126	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

DNase	NULL
footprint	NULL
analysis	NULL
was	NULL
also	NULL
performed	NULL
with	NULL
PMA-stimulated	NULL
U937	NULL
nuclear	NULL
extracts	NULL
and	NULL
both	NULL
sense-labeled	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
and	NULL
antisense-labeled	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
probes	NULL
.	NULL

As	NULL
with	NULL
the	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extracts	NULL
,	NULL
experiments	NULL
employing	NULL
U937	NULL
nuclear	NULL
extracts	NULL
showed	NULL
a	NULL
footprint	NULL
upstream	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
;	NULL
with	NULL
the	NULL
sense-labeled	NULL
probe	NULL
,	NULL
a	NULL
footprint	NULL
between	NULL
positions	NULL
-117	NULL
and	NULL
-124	NULL
was	NULL
seen	NULL
,	NULL
and	NULL
with	NULL
the	NULL
antisense-labeled	NULL
probe	NULL
,	NULL
a	NULL
protected	NULL
region	NULL
was	NULL
noted	NULL
between	NULL
positions	NULL
-119	NULL
and	NULL
-126	NULL
.	NULL

DNase	NULL
protection	NULL
assays	NULL
were	NULL
also	NULL
performed	NULL
with	NULL
unstimulated	NULL
Jurkat	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
,	NULL
and	NULL
these	NULL
experiments	NULL
revealed	NULL
a	NULL
larger	NULL
protected	NULL
sequence	NULL
which	NULL
encompassed	NULL
a	NULL
region	NULL
between	NULL
positions	NULL
-127	NULL
,	NULL
17	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
xB	NULL
site	NULL
,	NULL
and	NULL
-110	NULL
,	NULL
which	NULL
is	NULL
the	NULL
endpoint	NULL
of	NULL
the	NULL
probe	NULL
and	NULL
the	NULL
start	NULL
of	NULL
the	NULL
kB	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
large	NULL
footprint	NULL
was	NULL
used	NULL
to	NULL
define	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
.	NULL

From	NULL
these	NULL
data	NULL
,	NULL
then	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
not	NULL
only	NULL
a	NULL
conserved	NULL
sequence	NULL
,	NULL
but	NULL
it	NULL
is	NULL
bound	NULL
by	NULL
one	NULL
or	NULL
more	NULL
nuclear	NULL
factors	NULL
found	NULL
in	NULL
monocytic	NULL
cells	NULL
,	NULL
unstimulated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
peri-B	NULL
site	NULL
disrupts	NULL
HIV-2	NULL
enhancer	NULL
function	NULL
in	NULL
monocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
peri-kB	NULL
site	NULL
to	NULL
mediate	NULL
HIV-2	NULL
enhancer	NULL
activation	NULL
,	NULL
we	NULL
introduced	NULL
site-specific	NULL
mutations	NULL
into	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
and	NULL
the	NULL
xB	NULL
site	NULL
of	NULL
an	NULL
HIV-2/CAT	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
sites	NULL
were	NULL
mutated	NULL
either	NULL
singly	NULL
or	NULL
in	NULL
combination	NULL
.	NULL

The	NULL
plasmid	NULL
desig-	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
A	NULL
I	NULL
0	NULL
1	NULL
I	NULL
a	NULL
LB	NULL
ANE	NULL
ILB	NULL
U	NULL
]	NULL
t*	NULL
+1	NULL
L	NULL
@	NULL
$	NULL
i	NULL
_	NULL
‘	NULL
IO	NULL
``	NULL
-|	NULL
CAGAAACAGCTGAGACTGCAGGGACTTTCCAGAAGGGG	NULL
GTCTTTGTCGACTCTGACGTCCCTGAAAGGTCTTCCCC	NULL
L____	NULL
L_____________J	NULL
B	NULL
HIV-2	NULL
ENHANCER	NULL
ACTIVATION	NULL
IN	NULL
MONOCYTES	NULL
BY	NULL
PERI-	NULL
«	NULL
B	NULL
4857	NULL
G	NULL
F	NULL
B	NULL
C	NULL
a	NULL
F	NULL
B	NULL
ug	NULL
protein	NULL
:	NULL
1	NULL
25	NULL
d	NULL
tren	NULL
:	NULL
#	NULL
s	NULL
@	NULL
tC	NULL
#	NULL
#	NULL
2	NULL
6	NULL
»	NULL
#	NULL
+	NULL
H	NULL
#	NULL
00+000~	NULL
«	NULL
b1~	NULL
#	NULL
=	NULL
@	NULL
i	NULL
&	NULL
i	NULL
e	NULL
..	NULL
®	NULL
.	NULL

*	NULL
n	NULL
*	NULL
#	NULL
«	NULL
#	NULL
ae	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
2	NULL
3	NULL
127	NULL
41	NULL
L	NULL
--	NULL
--	NULL
-	NULL
]	NULL
Dau	NULL
laa	NULL
ke	NULL
.	NULL

s.	NULL
GAAACAGC	NULL
TGAGACTGCAGATCTTTTCC	NULL
CTTTGTCGACTCTGACGTCTAGAAAAGG	NULL
L________J	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

DNase	NULL
protection	NULL
assays	NULL
demonstrate	NULL
a	NULL
footprint	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

DNase	NULL
protection	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
,	NULL
22	NULL
,	NULL
49	NULL
)	NULL
.	NULL

The	NULL
DNase	NULL
protection	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
150	NULL
pg	NULL
of	NULL
unstimulated	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extract	NULL
and	NULL
an	NULL
antisense	NULL
strand	NULL
probe	NULL
(	NULL
A	NULL
)	NULL
,	NULL
25	NULL
ug	NULL
of	NULL
U937	NULL
nuclear	NULL
extract	NULL
and	NULL
a	NULL
sense	NULL
strand	NULL
probe	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
1	NULL
or	NULL
25	NULL
ug	NULL
of	NULL
U937	NULL
nuclear	NULL
extract	NULL
and	NULL
an	NULL
antisense	NULL
strand	NULL
probe	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
and	NULL
«	NULL
B	NULL
elements	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
gels	NULL
,	NULL
with	NULL
dots	NULL
indicating	NULL
the	NULL
bases	NULL
which	NULL
constitute	NULL
the	NULL
xB	NULL
site	NULL
and	NULL
brackets	NULL
indicating	NULL
the	NULL
protected	NULL
bases	NULL
.	NULL

The	NULL
probe	NULL
used	NULL
for	NULL
Fig	NULL
.	NULL

2B	NULL
and	NULL
C	NULL
contained	NULL
mutated	NULL
«	NULL
B	NULL
and	NULL
PuB2	NULL
sites	NULL
.	NULL

G	NULL
,	NULL
G	NULL
ladder	NULL
;	NULL
F	NULL
,	NULL
free	NULL
probe	NULL
;	NULL
B	NULL
,	NULL
bound	NULL
probe	NULL
.	NULL

nated	NULL
Aperi-kB	NULL
(	NULL
A	NULL
)	NULL
contains	NULL
a	NULL
site-directed	NULL
mutation	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
,	NULL
and	NULL
the	NULL
plasmid	NULL
designated	NULL
Aperi-contains	NULL
a	NULL
mutation	NULL
near	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
site	NULL
.	NULL

The	NULL
peri-	NULL
«	NULL
kB	NULL
DEL	NULL
,	NULL
_	NULL
;	NULL
;	NULL
,	NULL
,	NULL
-12	NULL
,	NULL
,	NULL
contains	NULL
a	NULL
site-directed	NULL
deletion	NULL
of	NULL
the	NULL
17	NULL
bp	NULL
constituting	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
.	NULL

The	NULL
plasmid	NULL
Aperi-contains	NULL
both	NULL
the	NULL
peri-kB	NULL
(	NULL
A	NULL
)	NULL
and	NULL
the	NULL
kB	NULL
mutations	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
transfected	NULL
into	NULL
the	NULL
Jurkat	NULL
and	NULL
CEM	NULL
T-cell	NULL
lines	NULL
and	NULL
several	NULL
monocytic	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
the	NULL
HL-60	NULL
immature	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
U937	NULL
promonocytic	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
the	NULL
THP-1	NULL
mature	NULL
monocytic	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
data	NULL
derived	NULL
from	NULL
these	NULL
experiments	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

In	NULL
Jurkat	NULL
cell	NULL
transfections	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
kB	NULL
site	NULL
produced	NULL
a	NULL
marked	NULL
reduction	NULL
in	NULL
the	NULL
response	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
to	NULL
PMA	NULL
.	NULL

However	NULL
,	NULL
neither	NULL
deletion	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
nor	NULL
mutations	NULL
within	NULL
the	NULL
site	NULL
had	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
responsiveness	NULL
of	NULL
the	NULL
enhancer	NULL
,	NULL
as	NULL
stimulation	NULL
with	NULL
PMA	NULL
consistently	NULL
led	NULL
to	NULL
a	NULL
>	NULL
20-fold	NULL
activation	NULL
of	NULL
the	NULL
mutant	NULL
enhancer	NULL
constructs	NULL
,	NULL
similar	NULL
to	NULL
levels	NULL
seen	NULL
with	NULL
the	NULL
wild-type	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
«	NULL
kB	NULL
site	NULL
produced	NULL
no	NULL
significant	NULL
effect	NULL
beyond	NULL
that	NULL
seen	NULL
following	NULL
mutation	NULL
of	NULL
«	NULL
kB	NULL
alone	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
transfection	NULL
experiments	NULL
using	NULL
CEM	NULL
cells	NULL
,	NULL
another	NULL
human	NULL
leu-kemic	NULL
T-cell	NULL
line	NULL
.	NULL

As	NULL
with	NULL
Jurkat	NULL
cells	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
xB	NULL
site	NULL
of	NULL
the	NULL
HIV-2/CAT	NULL
construct	NULL
in	NULL
CEM	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
dramatic	NULL
decrease	NULL
in	NULL
the	NULL
enhancer	NULL
response	NULL
to	NULL
PMA	NULL
,	NULL
whereas	NULL
mutation	NULL
or	NULL
deletion	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
inducible	NULL
enhancer	NULL
function	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
HL-60	NULL
cells	NULL
,	NULL
the	NULL
wild-type	NULL
HIV-2/CAT	NULL
construct	NULL
was	NULL
markedly	NULL
activated	NULL
(	NULL
43-fold	NULL
)	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
seen	NULL
in	NULL
the	NULL
Jurkat	NULL
and	NULL
CEM	NULL
transfections	NULL
,	NULL
experiments	NULL
employing	NULL
either	NULL
the	NULL
Aperi-kB	NULL
(	NULL
A	NULL
)	NULL
or	NULL
Aperi-kB	NULL
(	NULL
B	NULL
)	NULL
mutant	NULL
construct	NULL
demonstrated	NULL
significantly	NULL
reduced	NULL
inducible	NULL
enhancer	NULL
function	NULL
in	NULL
the	NULL
HL-60	NULL
cells	NULL
,	NULL
an	NULL
effect	NULL
which	NULL
was	NULL
further	NULL
enhanced	NULL
by	NULL
mutation	NULL
of	NULL
kB	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
peri-kB	NULL
(	NULL
A	NULL
)	NULL
mutation	NULL
(	NULL
threefold	NULL
activation	NULL
of	NULL
the	NULL
Aperi-kB	NULL
(	NULL
A	NULL
)	NULL
mutant	NULL
compared	NULL
with	NULL
less	NULL
than	NULL
onefold	NULL
activation	NULL
using	NULL
the	NULL
double	NULL
mutant	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
peri-xB	NULL
site	NULL
also	NULL
resulted	NULL
in	NULL
significantly	NULL
reduced	NULL
enhancer	NULL
function	NULL
.	NULL

Results	NULL
similar	NULL
to	NULL
these	NULL
were	NULL
seen	NULL
in	NULL
transfection	NULL
experiments	NULL
using	NULL
the	NULL
mature	NULL
monocytic	NULL
cell	NULL
line	NULL
THP-1	NULL
,	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
leading	NULL
to	NULL
a	NULL
marked	NULL
reduction	NULL
in	NULL
the	NULL
level	NULL
of	NULL
PMA-induced	NULL
enhancer	NULL
function	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
U937	NULL
monocytic	NULL
cell	NULL
line	NULL
,	NULL
transfections	NULL
using	NULL
mutant	NULL
Aperi-B	NULL
(	NULL
A	NULL
)	NULL
or	NULL
Aperi-	NULL
«	NULL
kB	NULL
(	NULL
B	NULL
)	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
enhancer	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
,	NULL
but	NULL
when	NULL
the	NULL
plasmid	NULL
containing	NULL
both	NULL
Aperi-kB	NULL
(	NULL
A	NULL
)	NULL
and	NULL
a	NULL
mutated	NULL
kB	NULL
site	NULL
was	NULL
employed	NULL
,	NULL
activation	NULL
declined	NULL
from	NULL
56-fold	NULL
with	NULL
the	NULL
wild-type	NULL
enhancer	NULL
to	NULL
only	NULL
2.5-fold	NULL
.	NULL

This	NULL
decline	NULL
represents	NULL
a	NULL
pronounced	NULL
reduction	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
PMA	NULL
to	NULL
activate	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
beyond	NULL
that	NULL
seen	NULL
with	NULL
the	NULL
kB	NULL
site	NULL
mutated	NULL
alone	NULL
:	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
was	NULL
activated	NULL
11.5-fold	NULL
by	NULL
PMA	NULL
(	NULL
4.8	NULL
%	NULL
acetylation	NULL
)	NULL
in	NULL
experiments	NULL
using	NULL
the	NULL
single	NULL
xB	NULL
site	NULL
mutant	NULL
compared	NULL
with	NULL
an	NULL
activation	NULL
of	NULL
only	NULL
2.5-fold	NULL
(	NULL
2.4	NULL
%	NULL
acetylation	NULL
)	NULL
with	NULL
both	NULL
xB	NULL
and	NULL
peri-	NULL
«	NULL
B	NULL
sites	NULL
mutated	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
the	NULL
peri-kB	NULL
site	NULL
is	NULL
important	NULL
for	NULL
the	NULL
function	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
monocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
binds	NULL
a	NULL
specific	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
which	NULL
is	NULL
different	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
order	NULL
to	NULL
further	NULL
characterize	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
site	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
radiolabeled	NULL
peri-kB	NULL
site	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
and	NULL
HL-60	NULL
cells	NULL
,	NULL
unstimulated	NULL
or	NULL
incubated	NULL
with	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Binding	NULL
characteristics	NULL
were	NULL
then	NULL
compared	NULL
with	NULL
those	NULL
found	NULL
in	NULL
EMSAs	NULL
which	NULL
employed	NULL
Jurkat	NULL
T-cell	NULL
extracts	NULL
.	NULL

A	NULL
specific	NULL
complex	NULL
was	NULL
observed	NULL
in	NULL
extracts	NULL
from	NULL
both	NULL
unstimulated	NULL
and	NULL
PMA-induced	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4858	NULL
CLARK	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Aperi-kB	NULL
-	NULL
Aperi-xB	NULL
-	NULL
Aperi-xB	NULL
_	NULL
peri-kB	NULL
PLASMID	NULL
:	NULL
HIV-2	NULL
AxB	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
A	NULL
)	NULL
/A	NULL
xB	NULL
DEL	NULL
.	NULL

|	NULL
I	NULL
I	NULL
1	NULL
1	NULL
I	NULL
1	NULL
1	NULL
I	NULL
1	NULL
Z	NULL
o	NULL
a	NULL
Pd	NULL
6	NULL
o	NULL
<	NULL
a*	NULL
FOLD	NULL
ACTIVATION	NULL
:	NULL
22.1	NULL
2.6	NULL
21.5	NULL
26.9	NULL
1.9	NULL
26.3	NULL
PMA	NULL
:	NULL
-	NULL
-+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-o	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
C	NULL
AperiB	NULL
-	NULL
Aperi-xB	NULL
-	NULL
Aperi-xB	NULL
_	NULL
peri-kB	NULL
PLASMID	NULL
:	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
A	NULL
)	NULL
/AxB	NULL
__	NULL
DEL	NULL
.	NULL

1	NULL
I	NULL
|	NULL
39.4	NULL
%	NULL
--	NULL
_	NULL
z	NULL
o	NULL
E	NULL
<	NULL
=	NULL
g	NULL
G	NULL
a	NULL
<	NULL
6	NULL
FOLD	NULL
ACTIVATION	NULL
:	NULL
PMA	NULL
:	NULL
-	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
/+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
4A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
significantly	NULL
diminished	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
peri-	NULL
«	NULL
kB	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
degree	NULL
by	NULL
the	NULL
slightly	NULL
shorter	NULL
peri-	NULL
«	NULL
kB	NULL
(	NULL
C	NULL
)	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
but	NULL
not	NULL
by	NULL
the	NULL
kB	NULL
site	NULL
,	NULL
a	NULL
mutant	NULL
xB	NULL
site	NULL
,	NULL
or	NULL
the	NULL
PuB1	NULL
site	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
.	NULL

With	NULL
HL-60	NULL
nuclear	NULL
extracts	NULL
,	NULL
there	NULL
was	NULL
again	NULL
a	NULL
specific	NULL
complex	NULL
seen	NULL
which	NULL
was	NULL
almost	NULL
completely	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
unlabeled	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
not	NULL
significantly	NULL
diminished	NULL
by	NULL
unrelated	NULL
competitor	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
.	NULL

Experiments	NULL
employing	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
showed	NULL
a	NULL
specific	NULL
nuclear	NULL
factor-peri-	NULL
«	NULL
B	NULL
complex	NULL
as	NULL
well	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
many	NULL
(	NULL
although	NULL
not	NULL
all	NULL
)	NULL
of	NULL
the	NULL
EMSA	NULL
experiments	NULL
using	NULL
U937	NULL
or	NULL
HL-60	NULL
nuclear	NULL
extracts	NULL
but	NULL
not	NULL
in	NULL
any	NULL
experiments	NULL
using	NULL
Jurkat	NULL
extracts	NULL
,	NULL
the	NULL
complex	NULL
appeared	NULL
much	NULL
more	NULL
prominent	NULL
following	NULL
PMA	NULL
treatment	NULL
of	NULL
the	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
and	NULL
B	NULL
,	NULL
lanes	NULL
2	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
constitutive	NULL
J.	NULL
ViroL	NULL
.	NULL

B	NULL
AperixB	NULL
-	NULL
Aperi-xB	NULL
-	NULL
Aperi-kB	NULL
_	NULL
peri-	NULL
«	NULL
B	NULL
PLASMID	NULL
:	NULL
HIV-2	NULL
AxB	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
A	NULL
)	NULL
/AxB	NULL
__	NULL
DEL	NULL
%	NULL
ACETYLATION	NULL
FOLD	NULL
ACTIVATION	NULL
:	NULL
43.4	NULL
4.2	NULL
3.2	NULL
5.4	NULL
<	NULL
1.0	NULL
8.9	NULL
PMA	NULL
:	NULL
0	NULL
-	NULL
4000	NULL
-	NULL
Foos	NULL
$	NULL
00-o	NULL
$	NULL
oo-	NULL
$	NULL
0	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
disrupts	NULL
HIV-2	NULL
enhancer	NULL
activation	NULL
in	NULL
monocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

HIV-2/CAT	NULL
constructs	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
indicated	NULL
sites	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
,	NULL
HL-60	NULL
monocytic	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
U937	NULL
monocytic	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Mutated	NULL
sites	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

The	NULL
bars	NULL
represent	NULL
percent	NULL
conversion	NULL
of	NULL
chloramphenicol	NULL
to	NULL
its	NULL
acetylated	NULL
form	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
PMA	NULL
.	NULL

Fold	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
ratio	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
in	NULL
PMA-treated	NULL
versus	NULL
resting	NULL
cells	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
two	NULL
(	NULL
HL-60	NULL
,	NULL
U937	NULL
)	NULL
or	NULL
three	NULL
(	NULL
Jurkat	NULL
)	NULL
representative	NULL
independent	NULL
experiments	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
at	NULL
least	NULL
four	NULL
times	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

peri	NULL
«	NULL
B	NULL
DEL	NULL
,	NULL
peri-	NULL
«	NULL
B	NULL
DEL	NULL
(	NULL
-114/-127y	NULL
binding	NULL
seen	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
additional	NULL
binding	NULL
activity	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
PMA	NULL
treatment	NULL
of	NULL
monocytes	NULL
but	NULL
not	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
these	NULL
findings	NULL
reflected	NULL
what	NULL
is	NULL
occurring	NULL
in	NULL
vivo	NULL
,	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
these	NULL
cells	NULL
were	NULL
used	NULL
to	NULL
perform	NULL
EMSAs	NULL
.	NULL

A	NULL
series	NULL
of	NULL
specific	NULL
complexes	NULL
was	NULL
seen	NULL
in	NULL
EMSAs	NULL
using	NULL
unstimulated	NULL
peripheral	NULL
blood	NULL
monocytic	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
peri-kB	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
were	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
peri-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
but	NULL
not	NULL
by	NULL
a	NULL
xB	NULL
oligonucleotide	NULL
.	NULL

EMSAs	NULL
using	NULL
peripheral	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
showed	NULL
two	NULL
specific	NULL
complexes	NULL
which	NULL
were	NULL
significantly	NULL
diminished	NULL
by	NULL
an	NULL
unlabeled	NULL
peri-xB	NULL
oligonucleotide	NULL
but	NULL
not	NULL
by	NULL
xB	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
DNA-protein	NULL
binding	NULL
was	NULL
markedly	NULL
different	NULL
between	NULL
the	NULL
two	NULL
cell	NULL
types	NULL
,	NULL
suggesting	NULL
the	NULL
possibility	NULL
of	NULL
binding	NULL
by	NULL
different	NULL
cell-specific	NULL
proteins	NULL
or	NULL
by	NULL
a	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
which	NULL
is	NULL
differentially	NULL
modified	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
types	NULL
,	NULL
thus	NULL
altering	NULL
the	NULL
binding	NULL
pattern	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
when	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
these	NULL
cells	NULL
used	NULL
in	NULL
EMSAs	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
DNA-protein	NULL
binding	NULL
was	NULL
dramatically	NULL
different	NULL
from	NULL
that	NULL
seen	NULL
in	NULL
extracts	NULL
from	NULL
resting	NULL
monocytes	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
EMSA	NULL
data	NULL
from	NULL
monocytic	NULL
cell	NULL
lines	NULL
,	NULL
suggesting	NULL
that	NULL
both	NULL
constitutive	NULL
and	NULL
inducible	NULL
peri-	NULL
«	NULL
kB	NULL
binding	NULL
activity	NULL
is	NULL
found	NULL
in	NULL
monocytes	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
regulation	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
both	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
is	NULL
dependent	NULL
upon	NULL
conserved	NULL
sequences	NULL
in	NULL
the	NULL
LTR	NULL
including	NULL
«	NULL
B	NULL
,	NULL
PuB1	NULL
,	NULL
PuB2	NULL
,	NULL
and	NULL
the	NULL
pets	NULL
site	NULL
(	NULL
35	NULL
,	NULL
49	NULL
,	NULL
51	NULL
)	NULL
.	NULL

We	NULL
have	NULL
now	NULL
shown	NULL
that	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
HIV-2	NULL
ENHANCER	NULL
ACTIVATION	NULL
IN	NULL
MONOCYTES	NULL
BY	NULL
PERI-	NULL
«	NULL
B	NULL
4859	NULL
A	NULL
PMA	NULL
:	NULL
=-	NULL
4	NULL
4+	NULL
+	NULL
+4	NULL
+	NULL
+	NULL
OB	NULL
PMA	NULL
:	NULL
O-	NULL
$	NULL
$	NULL
$	NULL
$	NULL
$	NULL
+	NULL
C	NULL
PMA	NULL
:	NULL
-	NULL
4+	NULL
$	NULL
4+	NULL
4+	NULL
4+	NULL
+	NULL
Competitor	NULL
:	NULL
None	NULL
Self	NULL
(	NULL
C	NULL
)	NULL
kB	NULL
&	NULL
B	NULL
PuB	NULL
)	NULL
|	NULL
pom	NULL
titor	NULL
:	NULL
N	NULL
Self	NULL
(	NULL
C	NULL
)	NULL
«	NULL
B	NULL
AB	NULL
Competitor	NULL
:	NULL
None	NULL
-	NULL
Self	NULL
(	NULL
C	NULL
)	NULL
«	NULL
B	NULL
&	NULL
BPuBi	NULL
petitor	NULL
:	NULL
one	NULL
xB	NULL
AB	NULL
pets	NULL
P	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
2	NULL
2	NULL
2	NULL
%	NULL
2	NULL
%	NULL
20	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
-	NULL
'Top	NULL
20	NULL
``	NULL
2020	NULL
``	NULL
2p	NULL
``	NULL
-	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
``	NULL
20	NULL
``	NULL
``	NULL
20	NULL
``	NULL
20	NULL
'	NULL
20	NULL
'	NULL
20	NULL
'	NULL
-	NULL
»	NULL
-	NULL
«	NULL
008	NULL
``	NULL
_	NULL
-	NULL
>	NULL
#	NULL
s	NULL
#	NULL
wen	NULL
@	NULL
@	NULL
ass	NULL
-*	NULL
@	NULL
®	NULL
--	NULL
«	NULL
-	NULL
a	NULL
as	NULL
as	NULL
10	NULL
2	NULL
3	NULL
40	NULL
50	NULL
60	NULL
7	NULL
1°	NULL
2	NULL
10	NULL
20	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binds	NULL
to	NULL
the	NULL
isolated	NULL
peri-B	NULL
site	NULL
in	NULL
cell	NULL
lines	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
peri-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
-111	NULL
to	NULL
-137	NULL
)	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
either	NULL
U937	NULL
(	NULL
A	NULL
)	NULL
,	NULL
HL-60	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
Jurkat	NULL
(	NULL
C	NULL
)	NULL
cells	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
,	NULL
which	NULL
were	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
+	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
probe	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
7	NULL
)	NULL
.	NULL

The	NULL
competitor	NULL
oligonucleotides	NULL
are	NULL
sequences	NULL
from	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
and	NULL
include	NULL
the	NULL
unlabeled	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
a	NULL
truncated	NULL
peri-B	NULL
site	NULL
(	NULL
-111	NULL
to	NULL
-135	NULL
)	NULL
indicated	NULL
as	NULL
(	NULL
C	NULL
)	NULL
in	NULL
the	NULL
figure	NULL
,	NULL
a	NULL
B	NULL
oligonucleotide	NULL
(	NULL
-93	NULL
to	NULL
-114	NULL
)	NULL
,	NULL
a	NULL
mutated	NULL
«	NULL
B	NULL
sequence	NULL
(	NULL
AxB	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
and	NULL
either	NULL
a	NULL
PuB1	NULL
site	NULL
(	NULL
-151	NULL
to	NULL
-182	NULL
)	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
or	NULL
a	NULL
sequence	NULL
containing	NULL
a	NULL
pets	NULL
site	NULL
and	NULL
a	NULL
mutated	NULL
PuB2	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
-131	NULL
to	NULL
-162	NULL
)	NULL
in	NULL
panel	NULL
B	NULL
.	NULL

The	NULL
arrow	NULL
in	NULL
each	NULL
figure	NULL
indicates	NULL
the	NULL
specific	NULL
DNA-peri-	NULL
«	NULL
B	NULL
factor	NULL
complex	NULL
.	NULL

in	NULL
addition	NULL
to	NULL
these	NULL
cis-acting	NULL
elements	NULL
there	NULL
is	NULL
another	NULL
functional	NULL
site	NULL
,	NULL
the	NULL
site	NULL
,	NULL
which	NULL
mediates	NULL
HIV-2	NULL
enhancer	NULL
activation	NULL
in	NULL
monocytic	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
peri-kB	NULL
site	NULL
alone	NULL
results	NULL
in	NULL
a	NULL
marked	NULL
reduction	NULL
in	NULL
inducible	NULL
enhancer	NULL
function	NULL
in	NULL
HL-60	NULL
and	NULL
THP-1	NULL
monocytic	NULL
cells	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
the	NULL
site	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
mutated	NULL
xB	NULL
site	NULL
causes	NULL
significant	NULL
disruption	NULL
of	NULL
enhancer	NULL
activity	NULL
in	NULL
U937	NULL
monocytic	NULL
cells	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
a	NULL
single	NULL
mutation	NULL
in	NULL
the	NULL
peri-kB	NULL
site	NULL
does	NULL
not	NULL
significantly	NULL
reduce	NULL
HIV-2	NULL
enhancer	NULL
induction	NULL
in	NULL
U937	NULL
cells	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
findings	NULL
;	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
disabling	NULL
HIV-2	NULL
enhancer	NULL
function	NULL
in	NULL
U937	NULL
cells	NULL
appears	NULL
to	NULL
require	NULL
mutation	NULL
of	NULL
more	NULL
than	NULL
one	NULL
enhancer	NULL
element	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Through	NULL
DNase	NULL
protection	NULL
analysis	NULL
and	NULL
EMSAs	NULL
,	NULL
we	NULL
have	NULL
further	NULL
demonstrated	NULL
that	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
bound	NULL
specifically	NULL
by	NULL
one	NULL
or	NULL
more	NULL
nuclear	NULL
factors	NULL
(	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
)	NULL
found	NULL
in	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
HeLa	NULL
cells	NULL
.	NULL

EMSAs	NULL
using	NULL
peripheral	NULL
blood	NULL
monocyte	NULL
nuclear	NULL
extracts	NULL
show	NULL
several	NULL
specific	NULL
complexes	NULL
.	NULL

Whether	NULL
these	NULL
complexes	NULL
represent	NULL
binding	NULL
of	NULL
multimeric	NULL
forms	NULL
or	NULL
degradation	NULL
products	NULL
of	NULL
a	NULL
single	NULL
protein	NULL
or	NULL
binding	NULL
of	NULL
distinct	NULL
proteins	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
unknown	NULL
and	NULL
will	NULL
require	NULL
further	NULL
investigation	NULL
.	NULL

Compatible	NULL
with	NULL
the	NULL
functional	NULL
data	NULL
,	NULL
the	NULL
binding	NULL
pattern	NULL
seen	NULL
with	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
is	NULL
different	NULL
from	NULL
that	NULL
seen	NULL
with	NULL
monocytic	NULL
nuclear	NULL
extracts	NULL
,	NULL
and	NULL
while	NULL
binding	NULL
activity	NULL
is	NULL
seen	NULL
in	NULL
resting	NULL
monocytic	NULL
cells	NULL
,	NULL
greater	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
a	NULL
change	NULL
in	NULL
the	NULL
binding	NULL
pattern	NULL
is	NULL
seen	NULL
following	NULL
stimulation	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
with	NULL
PMA	NULL
.	NULL

Additional	NULL
studies	NULL
will	NULL
be	NULL
needed	NULL
to	NULL
determine	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
a	NULL
short	NULL
motif	NULL
in	NULL
the	NULL
antisense	NULL
strand	NULL
(	NULL
CTTTG	NULL
)	NULL
,	NULL
the	NULL
peri-kB	NULL
site	NULL
bears	NULL
little	NULL
similarity	NULL
to	NULL
the	NULL
region	NULL
upstream	NULL
of	NULL
kB	NULL
in	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
which	NULL
is	NULL
recognized	NULL
by	NULL
hLEF/TCF-l	NULL
«	NULL
(	NULL
5	NULL
,	NULL
70	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
hLEF/TCF-1	NULL
«	NULL
appears	NULL
to	NULL
be	NULL
specific	NULL
to	NULL
lymphoid	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
factor	NULL
recognizing	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
is	NULL
present	NULL
in	NULL
monocytes	NULL
and	NULL
HeLa	NULL
cells	NULL
in	NULL
addition	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
search	NULL
of	NULL
the	NULL
Transcription	NULL
Factor	NULL
Database	NULL
(	NULL
27	NULL
)	NULL
for	NULL
similari-	NULL
ties	NULL
between	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
peri-xB	NULL
site	NULL
and	NULL
sequences	NULL
of	NULL
known	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
revealed	NULL
some	NULL
similarity	NULL
to	NULL
two	NULL
known	NULL
binding	NULL
sites	NULL
.	NULL

One	NULL
of	NULL
these	NULL
sites	NULL
is	NULL
located	NULL
in	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
and	NULL
is	NULL
known	NULL
as	NULL
the	NULL
GT-IIB	NULL
motif	NULL
(	NULL
ACAGCTG	NULL
;	NULL
72	NULL
)	NULL
,	NULL
and	NULL
the	NULL
other	NULL
is	NULL
present	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
enhancers	NULL
and	NULL
binds	NULL
helix-loop-helix	NULL
proteins	NULL
,	NULL
and	NULL
is	NULL
known	NULL
as	NULL
the	NULL
E2-box	NULL
sequence	NULL
(	NULL
RCAGNTG	NULL
;	NULL
54	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
yet	NULL
known	NULL
whether	NULL
the	NULL
factors	NULL
which	NULL
bind	NULL
these	NULL
elements	NULL
are	NULL
similar	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
.	NULL

A	NULL
potential	NULL
interaction	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
mediating	NULL
transcriptional	NULL
activation	NULL
is	NULL
suggested	NULL
by	NULL
several	NULL
ob-servations	NULL
.	NULL

The	NULL
two	NULL
enhancer	NULL
sites	NULL
lie	NULL
in	NULL
close	NULL
proximity	NULL
to	NULL
one	NULL
another	NULL
in	NULL
the	NULL
HIV-2	NULL
LTR	NULL
,	NULL
and	NULL
DNase	NULL
footprint	NULL
analysis	NULL
in	NULL
HeLa	NULL
cells	NULL
shows	NULL
a	NULL
footprint	NULL
overlapping	NULL
both	NULL
the	NULL
kB	NULL
and	NULL
peri-kB	NULL
sites	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
synergistic	NULL
decline	NULL
in	NULL
inducible	NULL
enhancer	NULL
function	NULL
seen	NULL
when	NULL
both	NULL
the	NULL
xB	NULL
and	NULL
peri-	NULL
«	NULL
B	NULL
sites	NULL
are	NULL
mutated	NULL
in	NULL
U937	NULL
cells	NULL
gives	NULL
weight	NULL
to	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
interact	NULL
functionally	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
do	NULL
not	NULL
bind	NULL
directly	NULL
to	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
EMSAs	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
in	NULL
EMSAs	NULL
that	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
is	NULL
partially	NULL
inducible	NULL
;	NULL
there	NULL
is	NULL
binding	NULL
in	NULL
unstimulated	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
enhanced	NULL
binding	NULL
is	NULL
usually	NULL
seen	NULL
in	NULL
EMSAs	NULL
using	NULL
PMA-treated	NULL
HL-60	NULL
and	NULL
U937	NULL
nuclear	NULL
extracts	NULL
.	NULL

Enhanced	NULL
binding	NULL
and	NULL
an	NULL
alteration	NULL
in	NULL
the	NULL
binding	NULL
pattern	NULL
are	NULL
consistently	NULL
seen	NULL
in	NULL
EMSAs	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
PMA-treated	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
cellular	NULL
activation	NULL
in	NULL
monocytes	NULL
causes	NULL
a	NULL
posttranslational	NULL
modification	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
and/or	NULL
an	NULL
interaction	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
with	NULL
additional	NULL
cellular	NULL
proteins	NULL
leading	NULL
to	NULL
enhanced	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
transcription	NULL
.	NULL

These	NULL
findings	NULL
would	NULL
not	NULL
be	NULL
incompatible	NULL
with	NULL
a	NULL
posttranslational	NULL
modification	NULL
involving	NULL
,	NULL
for	NULL
example	NULL
,	NULL
phos-phorylation	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
.	NULL

Alternatively	NULL
or	NULL
addition-ally	NULL
,	NULL
an	NULL
interaction	NULL
between	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
and	NULL
another	NULL
cellular	NULL
factor	NULL
,	NULL
such	NULL
as	NULL
NF-kB	NULL
,	NULL
might	NULL
mediate	NULL
transcriptional	NULL
activation	NULL
.	NULL

4860	NULL
CLARK	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

ACompetitor	NULL
:	NULL
None	NULL
Self	NULL
xB	NULL
BCompetitor	NULL
:	NULL
None	NULL
Self	NULL
kB	NULL
C	NULL
PMA	NULL
:	NULL
-o	NULL
$	NULL
o	NULL
oo	NULL
$	NULL
o	NULL
$	NULL
o	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
e	NULL
I	NULL
?	NULL

20	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
I	NULL
|20||20|	NULL
Competitor	NULL
:	NULL
None	NULL
Self	NULL
kB	NULL
AB	NULL
Amount	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
I	NULL
1	NULL
I	NULL
“	NULL
;	NULL
T	NULL
T	NULL
-B	NULL
=I	NULL
-	NULL
»	NULL
-	NULL
>	NULL
1°	NULL
2	NULL
3	NULL
10	NULL
bos	NULL
,	NULL
W	NULL
#	NULL
#	NULL
<	NULL
2	NULL
3	NULL
4	NULL
5	NULL
2	NULL
3	NULL
1	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Specific	NULL
nuclear	NULL
factors	NULL
bind	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
using	NULL
the	NULL
same	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
(	NULL
A	NULL
)	NULL
or	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
probe	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
an	NULL
unlabeled	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
and	NULL
a	NULL
«	NULL
B	NULL
oligonucleotide	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
extracts	NULL
from	NULL
either	NULL
unstimulated	NULL
peripheral	NULL
monocytes	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
monocytes	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
probe	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
unlabeled	NULL
peri-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
xB	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
or	NULL
a	NULL
mutated	NULL
xB	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
in	NULL
each	NULL
figure	NULL
indicate	NULL
the	NULL
specific	NULL
DNA-peri-	NULL
«	NULL
B	NULL
factor	NULL
complexes	NULL
from	NULL
uninduced	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
induced	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
in	NULL
panel	NULL
C	NULL
)	NULL
cell	NULL
extracts	NULL
.	NULL

The	NULL
monocyte-specific	NULL
function	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
is	NULL
a	NULL
significant	NULL
and	NULL
unusual	NULL
feature	NULL
for	NULL
an	NULL
HIV	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
such	NULL
an	NULL
enhancer	NULL
element	NULL
has	NULL
not	NULL
been	NULL
described	NULL
previously	NULL
for	NULL
HIV-2	NULL
nor	NULL
clearly	NULL
shown	NULL
for	NULL
HIV-1	NULL
.	NULL

Nakanishi	NULL
et	NULL
al	NULL
.	NULL

have	NULL
described	NULL
a	NULL
cis-acting	NULL
element	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
known	NULL
as	NULL
URE	NULL
(	NULL
which	NULL
spans	NULL
the	NULL
site	NULL
recognized	NULL
by	NULL
hLEF/TCF-1	NULL
@	NULL
)	NULL
,	NULL
which	NULL
may	NULL
have	NULL
cell	NULL
type-specific	NULL
function	NULL
(	NULL
57	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
deletion	NULL
of	NULL
this	NULL
element	NULL
has	NULL
resulted	NULL
in	NULL
only	NULL
a	NULL
very	NULL
modest	NULL
decrease	NULL
in	NULL
transcription	NULL
in	NULL
MOLT-4	NULL
T	NULL
cells	NULL
and	NULL
U937	NULL
cells	NULL
(	NULL
4.3-	NULL
and	NULL
1.6-fold	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
transcription	NULL
in	NULL
other	NULL
T-cell	NULL
lines	NULL
(	NULL
57	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
studies	NULL
employed	NULL
large	NULL
deletions	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
a	NULL
technique	NULL
which	NULL
modifies	NULL
the	NULL
spatial	NULL
orientation	NULL
of	NULL
the	NULL
enhancer	NULL
and	NULL
often	NULL
removes	NULL
multiple	NULL
enhancer	NULL
elements	NULL
,	NULL
making	NULL
it	NULL
difficult	NULL
to	NULL
interpret	NULL
the	NULL
contributions	NULL
of	NULL
individual	NULL
elements	NULL
.	NULL

Several	NULL
other	NULL
studies	NULL
have	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
another	NULL
element	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
,	NULL
the	NULL
USF	NULL
binding	NULL
site	NULL
,	NULL
also	NULL
acts	NULL
in	NULL
a	NULL
cell	NULL
type-specific	NULL
manner	NULL
,	NULL
but	NULL
the	NULL
data	NULL
thus	NULL
far	NULL
appear	NULL
contradictory	NULL
(	NULL
45	NULL
,	NULL
46	NULL
,	NULL
53	NULL
,	NULL
73	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
PuB	NULL
and	NULL
pets	NULL
sites	NULL
was	NULL
described	NULL
,	NULL
with	NULL
its	NULL
effects	NULL
apparently	NULL
cell	NULL
line	NULL
specific	NULL
(	NULL
4	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
again	NULL
used	NULL
deletion	NULL
rather	NULL
than	NULL
site-specific	NULL
mu-tants	NULL
,	NULL
and	NULL
deletion	NULL
of	NULL
this	NULL
site	NULL
resulted	NULL
in	NULL
increased	NULL
basal	NULL
but	NULL
not	NULL
inducible	NULL
transcription	NULL
of	NULL
HIV-2/CAT	NULL
constructs	NULL
in	NULL
CEM	NULL
cells	NULL
.	NULL

These	NULL
effects	NULL
were	NULL
not	NULL
seen	NULL
in	NULL
U937	NULL
cells	NULL
or	NULL
HeLa	NULL
cells	NULL
,	NULL
and	NULL
they	NULL
did	NULL
not	NULL
appear	NULL
specific	NULL
to	NULL
T	NULL
cells	NULL
in	NULL
general	NULL
,	NULL
as	NULL
dele-	NULL
tion	NULL
of	NULL
this	NULL
site	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
had	NULL
minimal	NULL
effect	NULL
on	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL

Given	NULL
that	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
is	NULL
present	NULL
at	NULL
least	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
monocytes	NULL
,	NULL
its	NULL
differential	NULL
function	NULL
among	NULL
cell	NULL
types	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
differential	NULL
expression	NULL
of	NULL
a	NULL
single	NULL
DNA-binding	NULL
protein	NULL
.	NULL

However	NULL
,	NULL
the	NULL
means	NULL
by	NULL
which	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
acts	NULL
in	NULL
a	NULL
cell	NULL
type-specific	NULL
manner	NULL
may	NULL
be	NULL
analogous	NULL
to	NULL
that	NULL
described	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
Oct-1	NULL
.	NULL

The	NULL
ubiquitous	NULL
Oct-1	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
which	NULL
binds	NULL
the	NULL
octamer	NULL
motif	NULL
ATTTGCAT	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
40	NULL
)	NULL
and	NULL
is	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
a	NULL
histone	NULL
H2B	NULL
gene	NULL
and	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
small	NULL
nuclear	NULL
RNA	NULL
genes	NULL
(	NULL
19	NULL
,	NULL
42	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Oct-1	NULL
to	NULL
induce	NULL
high-level	NULL
,	NULL
octamer-dependent	NULL
transcription	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
distinct	NULL
B-cell-specific	NULL
factor	NULL
(	NULL
47	NULL
,	NULL
60	NULL
)	NULL
,	NULL
thus	NULL
providing	NULL
evidence	NULL
that	NULL
interactions	NULL
of	NULL
cell	NULL
type-specific	NULL
cofactors	NULL
with	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
are	NULL
a	NULL
mechanism	NULL
for	NULL
tissue-specific	NULL
function	NULL
.	NULL

The	NULL
monocyte-specific	NULL
activity	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
,	NULL
then	NULL
,	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
its	NULL
interaction	NULL
with	NULL
a	NULL
cofactor	NULL
whose	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
monocytes	NULL
.	NULL

The	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
an	NULL
important	NULL
element	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
.	NULL

While	NULL
it	NULL
binds	NULL
one	NULL
or	NULL
more	NULL
specific	NULL
nuclear	NULL
factors	NULL
from	NULL
both	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
its	NULL
functional	NULL
activity	NULL
is	NULL
apparent	NULL
in	NULL
monocytic	NULL
cells	NULL
but	NULL
not	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
monocyte-specific	NULL
function	NULL
of	NULL
this	NULL
element	NULL
could	NULL
be	NULL
important	NULL
for	NULL
understanding	NULL
the	NULL
dif-	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
HIV-2	NULL
ENHANCER	NULL
ACTIVATION	NULL
IN	NULL
MONOCYTES	NULL
BY	NULL
PERI-	NULL
«	NULL
B	NULL
4861	NULL
ferent	NULL
roles	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
play	NULL
in	NULL
HIV	NULL
pathogenesis	NULL
.	NULL

Further	NULL
studies	NULL
,	NULL
including	NULL
purification	NULL
and	NULL
cloning	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
B	NULL
factor	NULL
,	NULL
are	NULL
in	NULL
progress	NULL
and	NULL
should	NULL
allow	NULL
a	NULL
more	NULL
definitive	NULL
understanding	NULL
of	NULL
the	NULL
function	NULL
of	NULL
the	NULL
peri-	NULL
«	NULL
kB	NULL
factor	NULL
in	NULL
activating	NULL
HIV-2	NULL
transcription	NULL
,	NULL
its	NULL
interaction	NULL
with	NULL
other	NULL
cellular	NULL
factors	NULL
,	NULL
and	NULL
perhaps	NULL
its	NULL
role	NULL
in	NULL
normal	NULL
monocyte	NULL
physiol-	NULL
ogy	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Gary	NULL
Nabel	NULL
,	NULL
in	NULL
whose	NULL
laboratory	NULL
the	NULL
Jurkat	NULL
and	NULL
HeLa	NULL
DNase	NULL
footprinting	NULL
experiments	NULL
were	NULL
performed	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
to	NULL
D.M.M	NULL
.	NULL

from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
CAO01479	NULL
and	NULL
AI30924	NULL
)	NULL
and	NULL
from	NULL
the	NULL
Life	NULL
and	NULL
Health	NULL
Insurance	NULL
Medical	NULL
Research	NULL
Fund	NULL
.	NULL

N.M.C	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
K08-AI0O1293	NULL
and	NULL
training	NULL
grant	NULL
T32AI07360	NULL
)	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Albert	NULL
,	NULL
J.	NULL
,	NULL
U.	NULL
Bredberg	NULL
,	NULL
F.	NULL
Chiodi	NULL
,	NULL
B.	NULL
Bottinger	NULL
,	NULL
E.	NULL
M.	NULL
Fenyo	NULL
,	NULL
E.	NULL
Norrby	NULL
,	NULL
and	NULL
G.	NULL
Biberfeld	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
new	NULL
pathogenic	NULL
human	NULL
retrovirus	NULL
of	NULL
West	NULL
African	NULL
origin	NULL
(	NULL
SBL-6669	NULL
)	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
HTLV-IV	NULL
,	NULL
LAV	NULL
and	NULL
HTLV-IIIB	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
3:3-10	NULL
.	NULL

2	NULL
.	NULL

Ancelle	NULL
,	NULL
R.	NULL
,	NULL
O.	NULL
Bletry	NULL
,	NULL
A.	NULL
C.	NULL
Baglin	NULL
,	NULL
F.	NULL
Brun-Vézinet	NULL
,	NULL
M.-A	NULL
.	NULL

Rey	NULL
,	NULL
and	NULL
P.	NULL
Godeau	NULL
.	NULL

1987	NULL
.	NULL

Long	NULL
incubation	NULL
period	NULL
for	NULL
HIV-2	NULL
infection	NULL
.	NULL

Lancet	NULL
i:688-689	NULL
.	NULL

3	NULL
.	NULL

Andreasson	NULL
,	NULL
P.-A	NULL
.	NULL

,	NULL
F.	NULL
Dias	NULL
,	NULL
J.	NULL
M.	NULL
T.	NULL
Goudiaby	NULL
,	NULL
A.	NULL
Naucler	NULL
,	NULL
and	NULL
G.	NULL
Biberfield	NULL
.	NULL

1989	NULL
.	NULL

HIV-2	NULL
infection	NULL
in	NULL
prenatal	NULL
women	NULL
in	NULL
Guinea-Bissau	NULL
,	NULL
abstr	NULL
.	NULL

M.	NULL
P.	NULL
G.	NULL
16	NULL
,	NULL
p.	NULL
1000	NULL
.	NULL

In	NULL
Abstracts	NULL
of	NULL
Proceedings	NULL
of	NULL
the	NULL
IV	NULL
International	NULL
Conference	NULL
on	NULL
AIDS	NULL
in	NULL
Africa	NULL
,	NULL
Marseilles	NULL
,	NULL
France	NULL
.	NULL

4	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Mohr	NULL
.	NULL

1994	NULL
.	NULL

Conditional	NULL
regulatory	NULL
elements	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

75:2253-2260	NULL
.	NULL

5	NULL
.	NULL

Carlsson	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
L.	NULL
Waterman	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
hLEF/TCF-10	NULL
HMG	NULL
protein	NULL
contains	NULL
a	NULL
context-dependent	NULL
transcriptional	NULL
activation	NULL
domain	NULL
that	NULL
induces	NULL
the	NULL
TCRa	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2418-2430	NULL
.	NULL

6	NULL
.	NULL

Chakrabarti	NULL
,	NULL
L.	NULL
,	NULL
M.	NULL
Guyader	NULL
,	NULL
M.	NULL
Alizon	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
and	NULL
P.	NULL
Sonigo	NULL
.	NULL

1987	NULL
.	NULL

Sequence	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
from	NULL
macaque	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
other	NULL
human	NULL
and	NULL
simian	NULL
retroviruses	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
328:543-547.	NULL
.	NULL

Clark	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Markovitz	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

.	NULL

Clark	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
M.	NULL
J.	NULL
Smith	NULL
,	NULL
J.	NULL
M.	NULL
Hilfinger	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Markovitz	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
enhancer	NULL
is	NULL
mediated	NULL
by	NULL
binding	NULL
sites	NULL
for	NULL
Elf-1	NULL
and	NULL
the	NULL
pets	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:5522-5528	NULL
.	NULL

9	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
D.	NULL
Guétard	NULL
,	NULL
F.	NULL
Brun-Vézinet	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
M.-A	NULL
.	NULL

Rey	NULL
,	NULL
M.	NULL
O.	NULL
Santos-Ferreira	NULL
,	NULL
A.	NULL
G.	NULL
Laurent	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
C.	NULL
Katlama	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
D.	NULL
Klat	NULL
J.	NULL
Champali	NULL
d	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1986	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
new	NULL
human	NULL
retrovirus	NULL
from	NULL
West	NULL
African	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Science	NULL
233:343-346	NULL
.	NULL

10	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
Guyader	NULL
,	NULL
D.	NULL
Guétard	NULL
,	NULL
M.	NULL
Salle	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1986	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
polymorphism	NULL
of	NULL
the	NULL
human	NULL
immune	NULL
deficiency	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
324:691-695	NULL
.	NULL

11	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
K.	NULL
Mansinho	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
D.	NULL
Guétard	NULL
,	NULL
V.	NULL
Favier	NULL
,	NULL
J.	NULL
Nina	NULL
,	NULL
M.	NULL
O.	NULL
Santos-Ferreira	NULL
,	NULL
J.	NULL
L.	NULL
Champalimaud	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
infection	NULL
associated	NULL
with	NULL
AIDS	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

316:1180-1185	NULL
.	NULL

12	NULL
.	NULL

Cortes	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Detels	NULL
,	NULL
D.	NULL
Aboulafia	NULL
,	NULL
X.	NULL
L.	NULL
Li	NULL
,	NULL
T.	NULL
Moudgil	NULL
,	NULL
M.	NULL
Alam	NULL
,	NULL
C.	NULL
Bonecker	NULL
,	NULL
A.	NULL
Gonzaga	NULL
,	NULL
L.	NULL
Oyafuso	NULL
,	NULL
M.	NULL
Tondo	NULL
,	NULL
C.	NULL
Boite	NULL
,	NULL
N.	NULL
Hammershlak	NULL
,	NULL
C.	NULL
Capitani	NULL
,	NULL
D.	NULL
J.	NULL
Slamon	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Ho	NULL
.	NULL

1989	NULL
.	NULL

HIV-1	NULL
,	NULL
HIV-2	NULL
and	NULL
HTLV-I	NULL
infections	NULL
in	NULL
high	NULL
risk	NULL
groups	NULL
in	NULL
Brazil	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

320:953-958	NULL
.	NULL

13	NULL
.	NULL

De	NULL
Cock	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
G.	NULL
Adjorlolo	NULL
,	NULL
E.	NULL
Ekpini	NULL
,	NULL
T.	NULL
Sibailly	NULL
,	NULL
J.	NULL
Kouadio	NULL
,	NULL
M.	NULL
Maran	NULL
,	NULL
K.	NULL
Brattegaard	NULL
,	NULL
K.	NULL
M.	NULL
Vetter	NULL
,	NULL
R.	NULL
Doorly	NULL
,	NULL
and	NULL
H.	NULL
D.	NULL
Gayle	NULL
.	NULL

1993	NULL
.	NULL

Epidemiology	NULL
and	NULL
transmission	NULL
of	NULL
HIV-2	NULL
.	NULL

JAMA	NULL
270:2083-2086	NULL
.	NULL

14	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebowitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

15	NULL
.	NULL

Dynan	NULL
,	NULL
W.	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1983	NULL
.	NULL

The	NULL
promoter-specific	NULL
transcription	NULL
factor	NULL
Sp1	NULL
binds	NULL
to	NULL
upstream	NULL
sequences	NULL
in	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

Cell	NULL
35:79-87	NULL
.	NULL

16	NULL
.	NULL

Embretson	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Zupancic	NULL
,	NULL
J.	NULL
L.	NULL
Ribas	NULL
,	NULL
A.	NULL
Burke	NULL
,	NULL
P.	NULL
Racz	NULL
,	NULL
K.	NULL
Tenner-Racz	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Haase	NULL
.	NULL

1993	NULL
.	NULL

Massive	NULL
covert	NULL
infection	NULL
of	NULL
helper	NULL
T	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
by	NULL
HIV	NULL
during	NULL
the	NULL
incubation	NULL
period	NULL
of	NULL
AIDS	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:359-362	NULL
.	NULL

17	NULL
.	NULL

Emerman	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Guyader	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Muesing	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
transactivator	NULL
is	NULL
different	NULL
from	NULL
that	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3755-3760	NULL
.	NULL

18	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
S.	NULL
M.	NULL
Schnittman	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
S.	NULL
Koenig	NULL
,	NULL
and	NULL
G.	NULL
Pantaleo	NULL
.	NULL

1991	NULL
.	NULL

NIH	NULL
Conference	NULL
.	NULL

Immunopathogenetic	NULL
mechanisms	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
infection	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

114:678-693.	NULL
go	NULL
1	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

Fletcher	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Heintz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1987	NULL
.	NULL

Purification	NULL
and	NULL
characterization	NULL
of	NULL
OTF-1	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
regulating	NULL
cell	NULL
cycle	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
histone	NULL
H2b	NULL
gene	NULL
.	NULL

Cell	NULL
51:773-781	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
D.	NULL
P.	NULL
Bednarik	NULL
.	NULL

1992	NULL
.	NULL

Mechanisms	NULL
of	NULL
HIV-1	NULL
latency	NULL
.	NULL

AIDS	NULL
6:3-16	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
C.	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Cytokine-induced	NULL
expression	NULL
of	NULL
HIV-1	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promono-cyte	NULL
cell	NULL
line	NULL
.	NULL

Science	NULL
238:800-802	NULL
.	NULL

Galas	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
A.	NULL
Schmitz	NULL
.	NULL

1978	NULL
.	NULL

DNase	NULL
footprinting	NULL
:	NULL
a	NULL
simple	NULL
method	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
protein-DNA	NULL
binding	NULL
specificity	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

5:3157-3170	NULL
.	NULL

Gao	NULL
,	NULL
F.	NULL
,	NULL
L.	NULL
Yue	NULL
,	NULL
A.	NULL
T.	NULL
White	NULL
,	NULL
P.	NULL
G.	NULL
Pappas	NULL
,	NULL
J.	NULL
Barchue	NULL
,	NULL
A.	NULL
P.	NULL
Hanson	NULL
,	NULL
B.	NULL
M.	NULL
Greene	NULL
,	NULL
P.	NULL
M.	NULL
Sharp	NULL
,	NULL
G.	NULL
M.	NULL
Shaw	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Hah	NULL
»	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
infection	NULL
by	NULL
genetically	NULL
diverse	NULL
SIVgy-related	NULL
HIV-2	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
358:495-499	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Markovits	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
R.	NULL
F.	NULL
Betts	NULL
,	NULL
and	NULL
M.	NULL
Popovic	NULL
.	NULL

1986	NULL
.	NULL

Virus	NULL
isolation	NULL
from	NULL
and	NULL
identification	NULL
of	NULL
HTLV-III/LAV-producing	NULL
cells	NULL
in	NULL
brain	NULL
tissue	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
AIDS	NULL
.	NULL

JAMA	NULL
256:2365-2371.	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Markovits	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
M.	NULL
H.	NULL
Kaplan	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
M.	NULL
Popovic	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
role	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
HTLV-II/LAV	NULL
infection	NULL
.	NULL

Science	NULL
233:215-219	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
C.	NULL
Ferrua	NULL
,	NULL
R.	NULL
Mitra	NULL
,	NULL
T.	NULL
Phipps	NULL
,	NULL
A.	NULL
Wahl	NULL
,	NULL
H.	NULL
C.	NULL
Lane	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Burke	NULL
.	NULL

1988	NULL
.	NULL

Efficient	NULL
isolation	NULL
and	NULL
propagation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
on	NULL
recombinant	NULL
colony-stimulating	NULL
factor	NULL
1-treated	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:1428-1441	NULL
.	NULL

Ghosh	NULL
,	NULL
D.	NULL
1990	NULL
.	NULL

A	NULL
relational	NULL
database	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:1749-1756	NULL
.	NULL

Gmelig-Meyling	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1980	NULL
.	NULL

Separation	NULL
of	NULL
human	NULL
blood	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
on	NULL
a	NULL
continuous	NULL
Percoll®	NULL
gradient	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
33:1-9	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

21044-1051	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:662-669	NULL
.	NULL

Gutierrez	NULL
,	NULL
C.	NULL
,	NULL
R.	NULL
R.	NULL
Bernabe	NULL
,	NULL
J.	NULL
Vega	NULL
,	NULL
and	NULL
M.	NULL
Kreisler	NULL
.	NULL

1979	NULL
.	NULL

Purification	NULL
of	NULL
human	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
by	NULL
a	NULL
discontinuous	NULL
density	NULL
gradient	NULL
of	NULL
Percoll®	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
29:57-63	NULL
.	NULL

Guyader	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Emerman	NULL
,	NULL
P.	NULL
Soniga	NULL
,	NULL
F.	NULL
Clavel	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1987	NULL
.	NULL

Genome	NULL
organization	NULL
and	NULL
transactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:662-669	NULL
.	NULL

Hannibal	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
N.	NULL
Clark	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1993	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
2	NULL
transcription	NULL
by	NULL
specific	NULL
T-cell	NULL
activation	NULL
signals	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:5035-5040	NULL
.	NULL

Hannibal	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

Multiple	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
enhancer	NULL
mediate	NULL
the	NULL
response	NULL
to	NULL
T	NULL
cell	NULL
receptor	NULL
stimulation	NULL
by	NULL
antigen	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
hybridoma	NULL
line	NULL
.	NULL

Blood	NULL
83:1839-1846	NULL
.	NULL

Hilfinger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
N.	NULL
Clark	NULL
,	NULL
M.	NULL
Smith	NULL
,	NULL
K.	NULL
Robinson	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Markovitz	NULL
.	NULL

1993	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
enhancer	NULL
in	NULL
monocytes	NULL
at	NULL
various	NULL
stages	NULL
of	NULL
differentiation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:4448-4453	NULL
.	NULL

Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
T.	NULL
Moudgill	NULL
,	NULL
and	NULL
M.	NULL
Alan	NULL
.	NULL

1989	NULL
.	NULL

Quantitation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
in	NULL
the	NULL
blood	NULL
of	NULL
infected	NULL
persons	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

321:1621-1625	NULL
.	NULL

Hojlyng	NULL
,	NULL
N.	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Kvinesdal	NULL
,	NULL
K.	NULL
Molbak	NULL
,	NULL
and	NULL
P.	NULL
Aaby	NULL
.	NULL

1989	NULL
.	NULL

Vertical	NULL
transmission	NULL
of	NULL
HIV-2	NULL
:	NULL
does	NULL
it	NULL
occur	NULL
?	NULL

,	NULL
abstr	NULL
.	NULL

G.	NULL
517	NULL
,	NULL
p.	NULL
1024	NULL
.	NULL

In	NULL
Abstracts	NULL
of	NULL
Proceedings	NULL
of	NULL
the	NULL
IV	NULL
International	NULL
Conference	NULL
on	NULL
AIDS	NULL
in	NULL
Africa	NULL
,	NULL
Marseilles	NULL
,	NULL
France	NULL
.	NULL

Kanki	NULL
,	NULL
P.	NULL
1989	NULL
.	NULL

Clinical	NULL
significance	NULL
of	NULL
HIV-2	NULL
infection	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL

AIDS	NULL
Clin	NULL
.	NULL

Rev	NULL
.	NULL

1989:95-108	NULL
.	NULL

Kanki	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

1991	NULL
.	NULL

Biologic	NULL
features	NULL
of	NULL
HIV-2	NULL
:	NULL
an	NULL
update	NULL
.	NULL

AIDS	NULL
Clin	NULL
.	NULL

Rev	NULL
.	NULL

1991:17-38	NULL
.	NULL

Kemler	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1990	NULL
.	NULL

Octamer	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
cell	NULL
type-specificity	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

4:1444-1449.	NULL
.	NULL

Kinter	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
W.	NULL
Maury	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Direct	NULL
and	NULL
cytokine-mediated	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4306-4312	NULL
.	NULL

LaBella	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
L.	NULL
Sive	NULL
,	NULL
R.	NULL
G.	NULL
Roeder	NULL
,	NULL
and	NULL
N.	NULL
Heintz	NULL
.	NULL

1989	NULL
.	NULL

Cell-cycle	NULL
regulation	NULL
of	NULL
a	NULL
human	NULL
histone	NULL
H2B	NULL
gene	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
H2b-subtype-specific	NULL
consensus	NULL
element	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

232-39	NULL
.	NULL

Leiden	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
Ets-related	NULL
transcription	NULL
factor	NULL
,	NULL
Elf-1	NULL
,	NULL
binds	NULL
to	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
regulatory	NULL
elements	NULL
that	NULL
are	NULL
required	NULL
for	NULL
inducible	NULL
frens-activation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5890-5897	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
multifaceted	NULL
retrovirus	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

46:5457-5468	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Effects	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
mutations	NULL
on	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
repli-cation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4115-4119	NULL
.	NULL

4862	NULL
,	NULL
46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

CLARK	NULL
ET	NULL
AL	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Touzjian	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
T.	NULL
Dorfman	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
repressive	NULL
sequences	NULL
within	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5226-5229	NULL
.	NULL

Luo	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
T.	NULL
Gerster	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
B	NULL
cell-derived	NULL
coactivator	NULL
potentiates	NULL
the	NULL
activation	NULL
of	NULL
immunoglobulin	NULL
promoters	NULL
by	NULL
octamer-binding	NULL
transcription	NULL
factors	NULL
.	NULL

Cell	NULL
71:231-241	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
1993	NULL
.	NULL

Infection	NULL
with	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
HIV-2	NULL
)	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

118:211-218	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Hannibal	NULL
,	NULL
V.	NULL
L.	NULL
Perez	NULL
,	NULL
C.	NULL
Gauntt	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIVs	NULL
)	NULL
:	NULL
a	NULL
specific	NULL
regulatory	NULL
element	NULL
in	NULL
HIV-2	NULL
responds	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:9098-9102	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
C.	NULL
Hannibal	NULL
,	NULL
M.	NULL
Smith	NULL
,	NULL
R.	NULL
Cossman	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3961-3965	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Smith	NULL
,	NULL
M.	NULL
Davis	NULL
,	NULL
J.	NULL
M.	NULL
Hilfinger	NULL
,	NULL
M.	NULL
C.	NULL
Hannibal	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
enhancer	NULL
is	NULL
dependent	NULL
on	NULL
purine	NULL
box	NULL
and	NULL
«	NULL
B	NULL
regulatory	NULL
elements	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5479-5484	NULL
.	NULL

Marlink	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Kanki	NULL
,	NULL
I.	NULL
Thior	NULL
,	NULL
K.	NULL
Travers	NULL
,	NULL
G.	NULL
Eisen	NULL
,	NULL
T.	NULL
Siby	NULL
,	NULL
L	NULL
Traore	NULL
,	NULL
C.-C.	NULL
Hsieh	NULL
,	NULL
M.	NULL
Ciré	NULL
Dia	NULL
,	NULL
E.-H.	NULL
Gueye	NULL
,	NULL
J.	NULL
Hellinger	NULL
,	NULL
A.	NULL
Guéye-Ndiaye	NULL
,	NULL
J.-L.	NULL
Sank-alé	NULL
,	NULL
I.	NULL
Ndoye	NULL
,	NULL
S.	NULL
Mboup	NULL
,	NULL
and	NULL
M.	NULL
Essex	NULL
.	NULL

1994	NULL
.	NULL

Reduced	NULL
rate	NULL
of	NULL
disease	NULL
development	NULL
after	NULL
HIV-2	NULL
infection	NULL
as	NULL
compared	NULL
to	NULL
HIV-1	NULL
.	NULL

Science	NULL
265	NULL
:	NULL
1587-1590	NULL
.	NULL

Moses	NULL
,	NULL
A.	NULL
V.	NULL
,	NULL
C.	NULL
Ibanez	NULL
,	NULL
R.	NULL
Gaynor	NULL
,	NULL
P.	NULL
Ghazal	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
role	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
control	NULL
elements	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
basal	NULL
and	NULL
Tat-mediated	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
primary	NULL
human	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:298-307	NULL
.	NULL

Murre	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Voronova	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1991	NULL
.	NULL

B-cell	NULL
and	NULL
myocyte-specific	NULL
E2-box-binding	NULL
factors	NULL
contain	NULL
E12/E47-like	NULL
subunits	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
:	NULL
1156-1160	NULL
.	NULL

Myers	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berzofsky	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
T.	NULL
F.	NULL
Smith	NULL
,	NULL
and	NULL
F.	NULL
Wong-Stall	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

1992	NULL
.	NULL

Human	NULL
retroviruses	NULL
and	NULL
AIDS	NULL
1992	NULL
.	NULL

Los	NULL
Alamos	NULL
National	NULL
Laboratory	NULL
,	NULL
Los	NULL
Alamos	NULL
,	NULL
N.Mex	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nakanishi	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Masamune	NULL
,	NULL
and	NULL
N.	NULL
Kobayashi	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
novel	NULL
cis-acting	NULL
element	NULL
that	NULL
controls	NULL
transcription	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
DNA	NULL
,	NULL
depending	NULL
on	NULL
cell	NULL
type	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:6334-6338	NULL
.	NULL

Orenstein	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
M.	NULL
S.	NULL
Meltzer	NULL
,	NULL
T.	NULL
Phipps	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1988	NULL
.	NULL

Cytoplasmic	NULL
assembly	NULL
and	NULL
accumulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
types	NULL
1	NULL
and	NULL
2	NULL
in	NULL
recombinant	NULL
human	NULL
colony-stimulating	NULL
factor-l-treated	NULL
human	NULL
monocytes	NULL
:	NULL
an	NULL
ultrastructural	NULL
study	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2578-2586	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
J.	NULL
Demarest	NULL
,	NULL
L.	NULL
Butini	NULL
,	NULL
M.	NULL
Montroni	NULL
,	NULL
C.	NULL
H.	NULL
Fox	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
D.	NULL
P.	NULL
Kotler	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

HIV	NULL
infection	NULL
is	NULL
active	NULL
and	NULL
progressive	NULL
in	NULL
lymphoid	NULL
tissue	NULL
during	NULL
the	NULL
clinically	NULL
latent	NULL
stage	NULL
of	NULL
disease	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:355-358	NULL
.	NULL

Pierani	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Heguy	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
of	NULL
61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

octamer-containing	NULL
promoters	NULL
by	NULL
cither	NULL
octamer-binding	NULL
transcription	NULL
factor	NULL
1	NULL
(	NULL
OTF-1	NULL
)	NULL
or	NULL
OTF-2	NULL
and	NULL
requirement	NULL
of	NULL
an	NULL
additional	NULL
B-cell-specific	NULL
component	NULL
for	NULL
optimal	NULL
transcription	NULL
of	NULL
immunoglobulin	NULL
promoters	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:6204-6215	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
E.	NULL
Dub	NULL
,	NULL
W.	NULL
C.	NULL
Timmer	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Justement	NULL
.	NULL

1991	NULL
.	NULL

Interleukin	NULL
6	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
in	NULL
infected	NULL
monocytic	NULL
cells	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
by	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:151-158	NULL
.	NULL

Queen	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1983	NULL
.	NULL

Immunoglobulin	NULL
gene	NULL
transcription	NULL
is	NULL
activated	NULL
by	NULL
downstream	NULL
sequence	NULL
elements	NULL
.	NULL

Cell	NULL
33:741-748	NULL
.	NULL

Ruef	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
Dickey	NULL
,	NULL
C.	NULL
A.	NULL
Schable	NULL
,	NULL
B.	NULL
Griffith	NULL
,	NULL
A.	NULL
E.	NULL
Williams	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
D'Aquila	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
second	NULL
case	NULL
of	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
due	NULL
to	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
in	NULL
the	NULL
United	NULL
States	NULL
:	NULL
the	NULL
clinical	NULL
implications	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

86:709-712	NULL
.	NULL

Saksela	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Stevens	NULL
,	NULL
P.	NULL
Rubenstein	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
mRNA	NULL
expression	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
predicts	NULL
disease	NULL
progression	NULL
independently	NULL
of	NULL
the	NULL
numbers	NULL
of	NULL
CD4+	NULL
lym-phocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:1104-1108	NULL
.	NULL

Schrier	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
McCutchan	NULL
,	NULL
J.	NULL
C.	NULL
Venable	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Wiley	NULL
.	NULL

1990	NULL
.	NULL

T-cell-induced	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3280-3288	NULL
.	NULL

Singh	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
P.	NULL
Sharp	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
conserved	NULL
motif	NULL
in	NULL
transcriptional	NULL
control	NULL
elements	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
319:154-158	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
I.-C.	NULL
Ho	NULL
,	NULL
P.	NULL
R.	NULL
Bohjanen	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
S.	NULL
Miesfeldt	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
B.	NULL
Karpinski	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1992.	NULL
cis-acting	NULL
sequences	NULL
required	NULL
for	NULL
inducible	NULL
interleukin-2	NULL
enhancer	NULL
function	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
protein	NULL
,	NULL
Elf-1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1043-1053	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
T.	NULL
M.	NULL
Welsh	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Differences	NULL
in	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
.	NULL

Response	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:4348-4354	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
B.	NULL
Petryniak	NULL
,	NULL
L-C.	NULL
Ho	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1992	NULL
.	NULL

Evolutionarily	NULL
conserved	NULL
sub-families	NULL
of	NULL
ets	NULL
proteins	NULL
display	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificities	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1391-1399	NULL
.	NULL

Waterman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1990	NULL
.	NULL

Purification	NULL
of	NULL
TCF-1	NULL
«	NULL
,	NULL
a	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
that	NULL
activates	NULL
the	NULL
T-cell	NULL
receptor	NULL
Ca	NULL
gene	NULL
enhancer	NULL
in	NULL
a	NULL
context-dependent	NULL
manner	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

2:621-636	NULL
.	NULL

Wiley	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
R.	NULL
D.	NULL
Schrier	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
,	NULL
P.	NULL
W.	NULL
Lampert	NULL
,	NULL
and	NULL
M.	NULL
B	NULL
.	NULL

A.	NULL
Oldstone	NULL
.	NULL

1986	NULL
.	NULL

Cellular	NULL
localization	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
within	NULL
the	NULL
brains	NULL
of	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
patients	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:7089-7093	NULL
.	NULL

Xiao	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
I	NULL
Davidson	NULL
,	NULL
D.	NULL
Ferrandon	NULL
,	NULL
R.	NULL
Rosales	NULL
,	NULL
M.	NULL
Vigneron	NULL
,	NULL
M.	NULL
Macchi	NULL
,	NULL
F.	NULL
Ruffenach	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1987	NULL
.	NULL

One	NULL
cell-specific	NULL
and	NULL
three	NULL
ubiquitous	NULL
nuclear	NULL
proteins	NULL
bind	NULL
in	NULL
vitro	NULL
to	NULL
overlapping	NULL
motifs	NULL
in	NULL
the	NULL
domain	NULL
B1	NULL
of	NULL
the	NULL
SV40	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3005-3013	NULL
.	NULL

Zeichner	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
J.	NULL
Y.	NULL
H.	NULL
Kim	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Alwine	NULL
.	NULL

1991	NULL
.	NULL

Linker-scanning	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:2436-2444	NULL
.	NULL

